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ABSTRACT 
Recent advances in the molecular bases of haemostasis have highlighted that 
endothelial thrombomodulin (TM) plays a critical role in local haemostasis by binding 
thrombin and subsequently converting protein C to its active form (APC). In addition, the 
binding of thrombin to TM drastically alters the thrombin’s procoagulant activities to 
anticoagulant activities. The lipid bilayer in which it resides serves as an essential 
‘cofactor’, locally concentrating and coordinating the appropriate alignment of reacting 
cofactors and substrates for protein C activation. On the other hand, liposomes have been 
extensively studied as cell membrane model as well as carrier for delivering certain 
vaccines, enzymes, drugs, or genes. In this study, antithrombotic liposomal TM conjugate 
was design and developed by combination of antithrombotic membrane protein TM into 
liposome through recombinant and bioorthogonal conjugation techniques, which 
providing a rational strategy for generating novel and potential antithrombotic agent. 
Namely, the liposomal TM conjugate mimics the native endothelial antithrombotic 
  vi 
mechanism of both TM and lipid components and thus is more forceful than current 
antithrombotic agent. 
First, an efficient and chemoselective liposome surface functionalization method 
was developed based on Staudinger ligation, in which a model compound carbohydrate 
derivative carrying a spacer with azide was conjugated onto the surface of preformed 
liposomes carrying a terminal triphenylosphine in PBS buffer (pH 7.4) and at room 
temperature. 
Second, recombinant TM containing the EGF-like domains 456 with an 
azidohomoalaine at the C-terminal has been expressed and incorporated into liposome to 
form antithrombotic liposomal TM conjugate via Staudinger ligation. In addition, another 
chemically selective liposomal surface functionalization method for antithrombotic 
liposomal TM conjugated has been developed based on copper-free click chemistry, 
which provides an alternative approach to improving reaction efficiency and stability and 
represents an optimal platform for exploring membrane protein’s activity of TM. 
In addition, chemically selective liposomal surface functionalization and 
liposomal microarray fabrication using azide-reactive liposomes has been developed and 
confirmed by fluorescence imaging, fluorescent dye releasing kinetics, and AFM 
techniques. The azide-reactive liposome provides a facile strategy for membrane-mimetic 
glyco-array fabrication, which may find important biological and biomedical applications 
such as studying carbohydrate–protein interactions and toxin and antibody screening. 
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CHAPTER I  
INTRODUCTION 
1.1. Thrombosis and endothelial thrombomodulin (TM) 
Thromboembolic diseases such as myocardial infarction, stroke, and 
thromboembolism are major public health problems with significant mortality and 
morbidity in the United States [1]. It has been considered that all these diseases are 
primarily disorder of platelet function and the coagulation. In the past decades, 
antiplatelet agents such as aspirin and ticlopidine and anticoagulant agents such as 
heparin and warfarin have been established and provided remarkable achievements in the 
treatment of thromboembolic diseases. However, these drugs have considerable 
limitations. In particular, the complications associated with bleeding represent a major 
drawback. Heparin and warfarin require laboratory monitoring, which are inconvenient to 
both patients and physicians and are costly. Furthermore, no beneficial effects in 
preventing restenosis after revascularization procedures have yet been obtained with the 
established antithrombotic agents. 
Recent understanding of haemostasis in the molecular bases has highlighted new 
targets for novel antithrombotic agent design. For example, antithrombotics aiming at 
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inactivating thrombin, inhibiting thrombin generation, inhibiting fibrin formation, 
inactivating coagulation cascade factors, destroying fibrin and interrupting platelet 
activity have been investigated widely [2]. In particular, selective inhibitors of thrombin 
and factor Xa, and components of the anticoagulant protein C system (recombinant 
activated human protein C or human soluble thrombomodulin) have been extensively 
studied. Some of these agents have had promising results in Phase III studies but still 
with limitations above. Given the limitations of the current antithrombotic agents, 
development of new antithrombotics with improved antithrombotic activity and reduction 
of unwanted bleeding and easier patient management is highly demanded. 
 
1.1.1 Endothelial TM Plays a Central Role in Local Haemostasis 
Thrombosis results
 
from a failure of haemostatic balance, which is normally 
maintained
 
by a complex series of coagulation reactions that involve both
 
systemic and 
local factors [3]. The endothelium contributes to
 
local haemostatic balance by producing 
thrombomodulin (TM), which
 
functions as an essential cofactor for the activation of 
anticoagulant
 
protein [4]. TM modulates the activity of
 
thrombin from a procoagulant to 
an anticoagulant protease [5].
 
To date, TM not only is a natural anticoagulant but also 
functions in anti-inflammatory (Figure 1.1) [6]. The anticoagulant function of TM was 
performed through protein C anticoagulant systems. In the protein C pathway, protein C 
will be activated to form activated protein C (APC) by thrombin, in which the speed of 
activation is very slow. After binding with TM on the surface of endothelial membrane, 
thrombin immediately enhances protein C activation by 1000 fold. On the one hand, APC 
produced in the pathway performed anticoagulant by inhibition of thrombin. Briefly, 
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APC binds protein S to form new complex after dissociating from endothelial cell protein 
C receptor (EPCR), which prevents thrombin generation by destroying factor FVa and 
FVIIIa. At same time, the inhibition of thrombin induces an indirect inflammation by 
preventing activation of protease-activated receptor (PAR)-1. On the other hand, APC-
EPCR complex anti-inflammatory effects via direct modulation of PAR-1[7]. 
 
Figure 1.1 Crosstalk Between Inflammation and Coagulation. Thrombin acts to form a 
positive feedback loop that augments coagulation and inflammation. In a negative 
feedback loop, the thrombin-TM complex activates protein C and downregulates 
coagulation and inflammation. APC, in tandem with its cofactor protein S, inactivates 
FVa and FVIIIa. In addition, the APC-EPCR complex induces anti-inflammatory effects 
through PARs. Therefore, thrombin, TM, and protein C-EPCR play pivotal roles in the 
crosstalk that occurs between inflammation and coagulation. Reproduced from [6] 
 
1.1.2 TM Structure and Function 
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As a natural anticoagulant protein, human TM, consisting of 557 amino acids, is 
mostly expressed on the surface of endothelium cell membranes and is structurally 
divided into five consecutive domain from amino terminal (Figure 1.2) [5]. C-type lectin 
domain, from N-terminal of TM, is responsible for mediating anti-inflammatory activities 
[8]. Adjacent to the lectin like domain is the epidermal growth factor (EGF)-like domain 
consisting of six repeat, which plays a key role in protein C activation and anticoagulant 
activity of TM. Although there remains unknown function for the first two EGF-like 
repeats (1-2), another three EGF-like repeats (4-6) have been studied very extensively 
and are responsible for whole activation of protein C [9]. Actually, EGF-like repeats 5-6 
do not involve protein C activation by itself, but are necessary for binding thrombin to 
TM via thrombin’s anion-binding exosite I. Differently, EGF like repeats 3-6 are 
responsible for activation of thrombin activatable fibrinolysis inhibitor (TAFI) [10]. After 
EGF like domain, there is O-linked glycosylation domain composing of serine/threonine, 
in which chondroitin sulfate is attached to TM to enhance protein C activation of TM by 
strengthening the thrombin-TM binding at anion-binding exosite 2 of Thrombin [11]. 
Next, a membrane spanning region consisting of 23 hydrophobic amino acids is linked to 
o-glycosylation domain. Finally, a short cytoplasmic domain containing a free cysteine is 
attached to C terminal in which cysteine may be responsible for meditation of 
multimerization to TM [12]. 
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Figure 1.2 TM Structure and the Model of Protein C Activation Complex. Thrombin 
binding to thrombomodulin involves anionbinding exosite 1 on thrombin and EGF 
domains 4 to 6 on thrombomodulin. A chondroitin sulfate moiety on thrombomodulin 
increases the affinity for thrombin by binding anion-binding exosite 2 on thrombin. The 
activation of protein C to APC by the thrombin-thrombomodulin complex is enhanced by 
binding to EPCR. Reproduced from [13]. 
 
1.1.3 Current Research on Exploring on the Therapeutic Applications of 
Recombinant TM  
It has been known that thromboembolic disorders
 
have been found to result from 
relative deficiency of TM [14] or protein C [15], and homozygous deficiency of TM has
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even been shown to confer lethality in mice [16]. The conversion of protein C to APC 
may be impaired during sepsis because of the down-regulation of TM by inflammatory 
cytokines [17]. The decrease in TM expression is associated with a local inflammatory
 
response [18], and transcription of the TM gene is known
 
to be negatively regulated by 
inflammatory cytokines such as
 
tumor necrosis factor (TNF)-α or interleukin-1 [19]. An 
alternative possibility is that TM may be shed from the endothelial surface by proteases 
produced
 
by activated leukocytes [20].
 
It has been demonstrated that local over-
expression of TM through adenoviral gene transfer can prevent thrombosis
 
in an animal 
model [21]. However, gene therapies currently are not
 
suitable to manage acute 
cardiovascular conditions.  
Recent studies have shown that recombinant human soluble TM (rhsTM, the extra 
cellular portion of TM) has a long biological half-life in the absence of significant 
systemic coagulation and produces dose-dependent anticoagulant and antithrombotic 
effects in both rodents and primates [22-25]. In tissue factor-infused monkeys, rhsTM 
pretreatment decreases the concentration of thrombin–antithrombin complexes in a dose-
dependent manner. Recombinant soluble TM is anticoagulant to various degrees in 
normal and protein C-depleted plasma [26]. A most recent study with a primate model 
demonstrated the antithrombotic effects of rhsTM were largely intact in the presence of 
protein C blocking antibody [27]. This study showed that pharmacological doses of 
rhsTM directly inhibited the prothrombotic response (thrombin generation) and 
upregulation of antithrombotic system (APC generation). This is in contrast to the 
conclusions of previous studies, which attributed the antithrombotic effects of rhsTM 
primarily to APC generation [28]. Therefore, rhsTM might exert anticoagulant effects by 
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at least two mechanisms: (1) directly, via direct thrombin inhibition and (2) indirectly, via 
supporting the thrombin/thrombomodulin-catalyzed local activation of protein C at the 
site of thrombin generation. 
  
1.1.4 Lipid Membranes Play a Pivotal Role in Regulating Blood Coagulation 
Reactions 
Both procoagulant and anticoagulant reactions occur at a physiologically 
significant rate only when the respective enzymes form multicomponent complexes on 
lipid membrane surfaces [29]. It has been observed that lipid vesicles containing 
negatively charged phospholipids, especially phosphatidylserine (PS), markedly enhance 
the rate of activation of procoagulant and anticoagulant enzymes [30, 31]. TM is a 
membrane protein of endothelium. The lipid bilayer in which it resides serves as an 
essential ‘cofactor’, locally concentrating and coordinating the appropriate alignment of 
reacting cofactors and substrates for protein C activation (Figure 1B). In concert with 
TM, the lipid membrane accelerates protein C activation and subsequently optimizes 
APC anticoagulant activity. Esmon et al. had demonstrated that TM incorporated into 
lipid vesicles resulted in substantially enhanced protein C activation [32].  The Km for 
protein C obtained with TM incorporated into lipid vesicles is very similar to that 
obtained on the endothelial cell surface. Studies also suggested that protein C prefers 
binding onto lipid membrane containing both phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) [33, 34]. On the other hand, efficient inactivation of 
Factor Va by APC requires the presence of negatively charged phospholipids, with 
phosphatidylserine (PS) being the most potent stimulator of the APC cleavage of Factor 
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Va [31]. In addition, incorporation of phosphatidylethanolamine (PE) into the 
phospholipid membrane has been found to enhance the inactivation of Factor Va by APC 
[35]. Therefore, lipid membrane is necessary to preserve TM’s activity and the lipid 
membrane recognition is necessary for both protein C activation and Factor Va 
inactivation and shares many properties in common with the endothelial cell surface.   
   
1. 2 Liposomes as Drug Delivery Vehicles 
1.2.1 Liposomes  
Liposomes, artificial microscopic and self-closed vesicles consisting of bilayer 
phospholipids membrane as model of biological cell membrane, have been studied 
extensively during the past few decades as drug delivery systems with great potential. 
Lipids as parts of natural membranes in live organism exit low immunogenicity and 
toxicity, good biocompatibility and biodegradability [36] and has been considered as a 
useful tool in genetic engineering and diagnostic techniques [37]. Additionally, due to 
their structure, chemical composition and colloidal size, liposomes are easily prepared as 
controlled size from microscale to nanoscale and surface functionalization through 
chemical biology with carbohydrate, peptide and protein [38-40]. 
Normally, liposomes are classified according to size and lamellarity. Small 
unilamellar vesicles (SUV) consist of a single lipid bilayer with 25-100 nm in size; large 
unilamellar vesicles (LUV) shows a diameter of 100-400 nm; multilamellar vesicles 
(MLV) consist of two or more concentric bilayers with a size range of 200 nm to several 
microns; multivesicular vesicles (MVV) usually have multicompartmental structure with 
more than 1 micrometer in size [41]. As cell-like compartments, liposomes’ size and 
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lamellarity with lipid composition play a vital role in modeling cell properties like the 
fluidity, permeability, stability [42].  In turn, liposomes could meet specific needs since 
the size, lamellarity and composition can be controlled and prepared by requirement. 
Since liposome has been recognized 40 years ago, several generation of liposome 
based drug delivery systems have been developed to overcome drawbacks such as short 
life time or non-targeting and diverse pharmaceutical criteria (Figure 1.3) [43].  
 
Figure 1.3 Evolution of Liposomes. A. Early traditional phospholipids ‘plain’ liposomes 
with water soluble drug in interior (a) or membrane (b). B. Antibody-targeted 
immunoliposome with antibody covalently coupled (c) or hydrophobically anchored (d) 
C. Long-circulating liposome grafted with a protective polymer (e) from opsonizing 
proteins (f). D. Long-circulating immunoliposome simultaneously bearing both protective 
polymer and antibody in the surface (g) or the chain end (h). E. New-generation 
liposome, the surface of which can be modified (separately or simultaneously) by 
different ways:  protective polymer (i&o), antibody (j), diagnostic label (k), charged 
lipids (l&n), DNA (m), peptide (p), viral components (q), magnetic particles (r), gold or 
silver particles (s). traditional liposomes. Reproduced from [43]. 
 
Early traditional liposomes are mainly comprised of natural phospholipids or 
lipids such as dipalmitoyl phosphatidil choline (DPPC, PC or egg phosphcholine), 
monosialoganglioside. As the first generation of liposome, although early traditional 
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liposomes have attracted a lot of attention in basic science research [44], they are limited 
to further application in pharmaceutical industry and clinical setting due to poor stability, 
short half-time and toxicity in some systems [45-47]. Many attempts have been made to 
remove those drawbacks.  For example, cholesterol was added to bilayer mixture to 
stabilize the structure of bilayer membrane [48]; liposome composed of egg lecithin was 
prepared by insertion of negative or positive charges to improve drug entrapment 
efficiency [49]; liposomes with different size range have been made to explore the effect 
of morphology of liposome on halt-time of liposome in the systemic circulation [50]. 
However, the major problems such as fast elimination and non-targeting still remain 
unresolved.  
 
1.2.2 Stealth Liposomes 
First breakthrough in the liposome development is stealth liposome or long-
circulating liposome. Stealth liposome strategy was achieved simply by coating the 
surface of liposome with a hydrophilic and biocompatible polymer-poly ethylene glycol 
(PEG). PEG provides a stereic barrier that prevents liposome aggregation and opsonizing 
proteins (Figure 1.3 C) [51]. Many other hydrophilic polymers such as chitosan [52], silk-
fibroin [53], and polyvinyl alcohol (PVA) [54] have been tried to increase half-time of 
liposome and reduce toxicity. Although those hydrophilic polymers could meet 
biodegradability, nontoxicity and lower immunogenicity, PEG still keep the gold 
standard in protecting liposome and increasing circulation time. Vaccines or anticancer 
therapeutics to non-viral gene therapy vectors sequesters part of the solvent, in which 
they freely float into their interior. In the case of one bilayer encapsulating the aqueous 
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core one speaks either of small or large unilamellar vesicles while in the case of many 
concentric bilayers one defines large multilamellar vesicles. All of which can be well 
controlled by preparation methods, liposomes exhibit several properties which may be 
useful in various applications. The most important properties are colloidal size, i.e. rather 
uniform particle size distributions in the range from 20 nm to 10 μm, and special 
membrane and surface characteristics. They include bilayer phase behavior, its 
mechanical properties and permeability, charge density, presence of surface bound or 
grafted polymers, or attachment of special ligands, respectively. Additionally, due to their 
amphiphilic character, liposomes are a powerful solubilizing system for a wide range of 
compounds. In addition to these physico-chemical properties, liposomes exhibit many 
special biological characteristics, including (specific) interactions with biological 
membranes and various cells [55]. 
 
1.2.3 Targeted Liposome 
The further development of liposome involves increasing liposomal drug 
accumulation in the desired tissues and organs, in other words, specific targeting of 
liposome based systems should be addressed (Figure 1.3 B, D&E). Overcoming the 
biological barriers between administration and the site of action of drug or gene is 
becoming increasingly important for the development of better and safer medicines. 
Small organic molecule-based drugs often suffer from poor bioavailability problems, 
such as limited water solubility and/or poor membrane permeability. Peptide, protein, or 
DNA-based biomacromolecules are even more challenging to develop safe and efficient 
drug products due to the size and poor biological stability as well as immunogenicity 
  12 
problems [57]. Targeted liposome increases noticeably the local drug concentration in the 
ideal tissue or cells without harmful side effect on healthy cells or/and systemic side 
effect [58-60]. Different types of targeting moieties such antibodies, peptide, 
glycoprotein, oligopeptide, polysaccharide, growth factors, folic acid, carbohydrate, 
receptors, and peptides have been extensively explored to conjugate liposome to 
overcome these limitations in the past decades [61-64].  
 
1.3 Current Methods for Liposome Surface Modification 
Liposomes as mimics of cell membrane have attracted much attention. 
Conjugation different ligands such as proteins, peptides and drugs to liposomes has been 
studied extensively in numerous applications. A number of conjugation methods have 
been developed for liposome surface functionalization and are described in the following.  
 
1.3.1 Direct Liposome Formation with Ligands 
To most of small ligands, surface modification of liposome through direct 
liposome formation is common method. This strategy involves the initial synthesis of the 
key lipid-ligand conjugate, followed by formulation of the liposome with all lipid 
components. In this direct liposome formation method, around 50% of total ligands 
inevitably are facing the interior of liposome and thus become unavailable for their 
intended interaction with their target molecules. This approach is well suited for ligands 
that are cheap and in large quantities, such as saccharides [65] and vitamins [66]. 
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1.3.2 Post-Insertion Approach 
Another method for liposome surface modification was developed to overcome 
problems in surface modification through direct liposome formation. In this approach, 
liposome was prepared firstly, and then functionalized ligands with lipid tailor will 
incorporate into performed liposome. Normally, targeted ligands will be covalenty 
attached with lipids and then dissolved into buffer to form micelles. Next, micelles 
containing ligands will mix with performed liposome to allow ligands incorporate into 
performed liposome by fusion. Lipid-ligand conjugates normally have limited solubility 
and stability in solvent, or are incompatible with various stages of manufacture. The 
advantages of this approach for liposome surface modification include reducing ligands 
amounts, noncovalent and reversible incorporation and make it suitable to antibody [67], 
protein [68] and peptides [69] incorporation into the liposome surface. On the other hand, 
this approach suffers from low incorporation efficiency and limited solubility and 
stability of ligands conjugates with lipid in solvent, as a result, limits its applications. 
 
1.3.3 Post-Functionalization Approach 
Chemical modification methods, namely post-functionalization, which in most 
cases involve the coupling of biomolecules to the surface of preformed vesicles that carry 
functionalized (phospho) lipid anchors, have been developed [70]. So far, variable 
coupling methods for post functionalization such amide or thiol-maleimide coupling as 
well as by imine or hydrazone linkage have been achieved. Below each coupling reaction 
for post liposome surface functionalization are described in detail (Figure 1.4). 
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Figure 1.4 Schematic Illustration of the Various Coupling Methods that have been 
Developed in order to Post-Functionalized Liposomes: a Amine functionalization, b 
carboxylic acid functionalization, c aldehyde functionalization, d hydrazine 
functionalization, e maleimide functionalization, f thiol functionalization, g thiol 
functionalization (disulfide bond formation), h bromoacetyl functionalization, i cysteine 
functionalization, j cyanur functionalization, k p-nitrophenylcarbonyl functionalization, l 
alkyne functionalization, m triphenylosphine functionalization. Reproduced from [71]. 
 
1.3.3.1 Traditional Covalent Conjugation 
Linkages containing amide bonds 
The amide bond, generally represented as RC(O)NH2, is very stable and widely 
used for surface modification by bioconjugation and becomes one of earliest methods to 
functionalize performed liposome. This linkage could be performed by coupling ligands 
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to amine functionalized liposomes or coupling ligands to carboxylic aicd modified 
liposomes. Since liposome is kind of water solution, water soluble carbodiimides, such as 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride [EDC] was used to allow 
for an aqueous conjugation reaction. And N-hydroxysulfosuccinimide [Sulfo-NHS] is 
used to form a stable intermediate (NHS ester derivatives) and followed by formation of 
amide bonds with high efficiency.  
Another poplar approach through linkage containing amine bonds is to exploit the 
reaction between aldehyde and hydrazide group (Figure 1.4d). Normally, hydrazide will 
be incorporated into liposome to attain hydrazide functionalized liposome which will 
react with aldehyde group in antibody or protein. This coupling is specially suited for 
preparation of antibody liposome conjugates [72]. Chua et al used this approach to attach 
immunoglobulin to liposome surface [73]. In this study, carbohydrate groups in the heavy 
chain of the immunoglobulin were oxidation to afford aldehyde in the help of galactose 
oxidase or sodium periodate. Finally, immunoglobulin was immobilized onto the surface 
of liposome by formation of amide bonds between aldehyde in the immunoglobulin and 
hydrazide in the surface of liposome. 
Additional amide bonds could be formed between p-nitrophenylcarbonyl group 
and primary amines (Figure 1.4 k). This method allows directly conjugation of antibodies 
into the liposome without additional modification. Torchilin et al successfully attached 
several proteins such as avidin, antimyosin antibody 2G4, wheat germ agglutinin and 
concanavalin into the liposome surface via a stable and non-toxic amide bond [74]. 
However, one main drawback of this approach lies in usage of bifunctional p-
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nitrophenylcarbonyl because this bifunctional molecule offers a possibility of cross-
linking.  
Linkages containg thioethers 
Considering thiol is another common group in the protein, the reaction of 
thioethers between protein and thiol-reactive liposome has been studied well for liposome 
surface modification. The thiol-reactive functional groups are kind of ankylating reagents 
including include iodoacetamides (Figure 1.5A), maleimides (Figure 1.5B), and 
disulfides (Figure 1.5C). Iodoacetamides easily react with thiols group in the proteins 
peptides and antibodies via formation of thioethers. Normally, they are more likely 
reactive with thiol group in the cysteine but may also react with ones in the tyrosine or 
histidine. For instance, Frisch et al. has successfully attached peptides containing cysteine 
to the surface of liposome functionalized with bromoacetyl [75]. This coupling reaction 
was performed at pH 9.0 and done in one hour. The reaction condition developed here 
did not alter the integrity of liposome and are harmless to liposome surface modification.  
The maleimide reaction is most effective and common approach in bioconjugation 
chemistry for surface modification due its high efficiency and selectivity with 
minimization of side reactions [Figure 1.5B]. This approach involves reaction of thiols in 
the proteins or peptides and double bond in the maleimides to form a stable thioether 
bond, allowing conjugation proteins or peptides covalently into liposome surface. A 
number of researches have been focused on liposome surface modification by maleimides 
reactions. For example, Garnier et al. recently immobilized the Annexin-A5 protein onto 
liposome surface modified with maleimides [76]. Another case is the selective 
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conjugation of thiolated OX26 monoclonal antibodies to DSPE-PEG-maleimide 
functionalized liposome [77].  
Compared to iodoacetamides and maleimide reaction, disulfides reaction is freely 
reversible and thiol specific. The new disulfide bond was formed through a thiol-disulfide 
exchange and therefore improves resistant to hydrolysis. Gyongyossy-Issa et al used this 
approach to successfully conjugate RGD-motif-containing peptide into liposomes by a 
thiol-disulfide exchange and provides a choice for target drug delivery [78] 
 
Figure 1.5 Bioconjugation via Thioethers or Disulfides. Reaction of a thiolate with (A) a 
haloacetamide, (B) a maleimide, and (C) a disulfide linkages. Reproduced from [79] 
 
Containing carbon–nitrogen double Bonds 
Bioconjugation via carbon–nitrogen double bonds by which ligands can be 
incorporated into liposome surface in physiological condition has received much 
attention. In this approach, nitrogen bases react with aldehydes and ketones to afford 
carbon-double bonds including hydrazones (C=N–N) and oximes (C=N–O). Nitrogen 
and Oxygen in the terminal of carbon-double bonds make it more stable compared to 
regular products of amines with aldehydes or ketones. A number of researches have been 
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conducted on liposome functionalization by antibodies or proteins by this strategy. In this 
strategy, aldehyde could be from ligands or performed liposome. Bonnet et al. 
successfully incorporate hydrazino-derivatized ligands to aldehyde functionalized 
liposomes via formation of hydrazone. In this study, functionalized anchor lipid 
(aldehyde functionalized ether lipid di-O-hexadecyl-rac-glyceraldehyde) was ynthesized 
firstly and used for liposome preparation; next, lysosome-associated membrane protein 
(LAMP) was modified by N,N,N-tri(tert-butyloxycarbonyl)-hydrazino acetic acid and 
then incubated into aldehyde functionalized liposome to afford LAMP liposome 
conjugate. In contrast, Torchilin et al.chose amine functionalized liposome for 
conjugation of rabbit anticanine cardiac myosin antibodies [80]. In this experiment, 
glutaraldehyde and dimethyl suberimidate are utilized for conjugation via formation of 
oximes. 
 
1.3.3.2 Bioorthogonal Conjugation 
To date, most of available conjugation methods are non-specific and less selective 
interaction, and also suffer from low efficiency and toxicity to living organism. As a 
result, there are less reliable and safe for living systems. Fortunately, a number of 
bioorthogonal reactions have been developed. Compared to traditional chemical methods, 
these bioorthogonal reactions have shown excellent biocompatibility and selectivity in 
living systems. Each of bioorthogonal reactions used for liposome surface modification 
will be discussed in detail. 
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Native chemical ligation 
Native chemical ligation is one of most widely used methods for chemical 
biology. This strategy was developed by Dawson et al to ligate large unprotected peptide 
fragments [81]. In this reaction, two unprotected peptide segments by the reaction of a α-
thioester with a cysteine-peptide can be connected at the physiological condition (Figure 
1.6). Numerous studies have been conducted on national chemical ligation and its 
applications such as protein synthesis, in vivo imagine, surface modification and protein 
array [82].  
 
 
Figure 1.6 Principle of Native Chemical Ligation. Reproduced from [82] 
Considering its chemoselectivity and high efficiency in physiological condition, 
Reulen et al. first introduced this ligation to liposome surface modification [83]. In this 
study, anchor lipid (DSPE-PEG-Cysteine) for native chemical ligation has been firstly 
synthesized and then was allowed to preparation of liposome containing anchor lipid. 
Next, Enhanced yellow fluorescent protein (EYFP) and a collagen-binding protein 
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domain (CNA35) modified with odium 2-mercaptoethanesulfonate (MESNA) were 
chosen to perform native chemical ligation. After incubation in HEPES buffer for 48h, 
cysteine functionalized liposome has been successfully modified by EYFP and CNA35. 
The strategy developed here provides an alternative method for liposome surface 
modification. 
 
Staudinger ligation 
The Staudinger ligation, in which an azide and triphenylosphine selectively react 
to form an amide, has been used for chemical selective modification of recombinant 
protein under native condition [84]. Recently, Staudinger ligation has been successfully 
performed in living animals without physiological harm, suggesting the potential for 
applications in cell surface functionalization [85]. Particularly, the reaction is known to 
occur in high yield at room temperature in aqueous solvents and without any catalyst, and 
is compatible with the unprotected functional groups of wide range of biomolecules. We 
have developed an efficient and chemically selective liposome surface functionalization 
with lactose as model carbohydrate through Staudinger ligation [38] (Figure 1.7). The 
high specificity and high yield as well as biocompatible reaction condition natures of the 
Staudinger ligation approach make it an attractive alternative to all current protocols for 
liposome surface functionalization. 
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Figure 1.7 Schematic Illustration of Liposome Surface Glyco-Functionalization through 
Staudinger Ligation. Reproduced from [38] 
 
Click chemistry 
As one of the most popular reactions for bioconjugation techniques in chemical 
biology, Click chemistry was developed by K. Barry Sharpless based on the 1, 3-dipolar 
cycloaddition reaction between azides and acetylenes to yield triazoles in 2001 [86]. In 
the reaction, an organic azide reacts with an alkyne to form a stable triazole ring under 
help of Cu (I) in aqueous conditions with high efficiency. Bothe of reactants-azide and 
alkyne are very inert and orthogonal to other chemical functionalities which offer this 
reaction high selectivity. Therefore, Click chemistry is extremely valuable in chemical 
biology by proving an excellent technology for bioconjugation and has attracted much 
attention in many areas such as protein modification, microarray, cell imaging and 
peptides synthesis. Hassane et al. successfully expanded this strategy into liposome 
surface functionalization [87]. First, anchor lipid N-[2-(2-(2-(2-(2,3-
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bis(hexadecyloxy)propoxy)ethoxy)ethoxy)-ethoxy)ethyl]hex-5-ynamide was synthesized 
in which alkyne group was inserted into the terminal of lipid for conjugation. Then, 
liposome with incorporation of anchor lipid above were prepared and followed to 
incubate with an azido-modified mannose ligand for 24 h. After evaluation of mannose 
onto the surface of liposome, this in situ surface modification showed around 25% yield. 
Another example for liposome surface modification was adopted by Cavalli et al. [88]. In 
this study, Alkyne functionality was inserted into the liposome surface by incorporating 
alkyne functionalized 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). A single 
amino acid α-azido-modified lysine was chosen and mixed together with alkyne 
functionalized liposome to perform this coupling reaction under help of Cu (I) (Figure 
1.8). Unfortunately, due to introduction of cooper as a catalyst, this strategy limited its 
wide application in living organism since cooper is heavy metal and could be toxic to 
living systems. 
 
Figure 1.8 Schematic Representation of the General Approach for the Chemical 
Modification of a Liposome Surface by Peptides via Copper (I)-Mediated [3+2] Azide-
Alkyne Cycloaddition. Reproduced from [88] 
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1.4 Incorporation of Unnatural Amino Acid for Protein Engineering through 
Synthetic Biology 
Unnatural amino acids (UAAs), unlike a standard set of 20 amino acids, are not 
basic blocks for building living organism in the earth but still represent an enormous 
amount of diverse structural elements and provide a great potential to build a new protein 
with novel function or enhance properties to meet numerous needs of life. Sometimes 
UAAs other than basic amino acids plays a vital role in biology activity. For example, as 
an inhibitory neurotransmitter, gamma-amino butyric acid helps neurons stay selective 
about the signals to which they respond with a state of relaxation [89]. Histamine as an 
UAAs involves in local immune response and mediates allergic reactions [90]. On the 
other hand, UAAs lead to protein or even organisms with enhanced function. Schultz et al 
first introduced UAA into protein with providing an opportunity to examine the 
evolutionary consequences as well as generate proteins with new or enhanced biological 
functions [91]. The replacement of the natural L-amino acids with unnatural D-amino 
acids can make the peptides resistant to protect themselves from degradation by 
peptidases [92]. 
 
1.4.1 Unnatural Amino Acid Incorporation 
The incorporation of UAAs into protein has attracted a lot of attention in chemical 
biology and pharmeautical industry. This strategy not only aims to improve physiological 
properties but also create artificial proteins for pharmeautical application. A variety of 
methods have been developed to explore the incorporation of UAAs into proteins. 
Herein, those methods for incorporation of UAAs have classified into three categories:  
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translational incorporation of UAAs, semi-synthetic incorporation and bio-orthogonal 
conjugation to UAAs and are described in the following. 
 
1.4.1.1 Translational Incorporation of UAAs 
 The use of UAAs auxotrophic strains is the oldest method for UAAs 
incorporation by use of auxotrophic Escherichia coli (E. Coli) strains. In this strategy, 
incorporation of UAA into recombinant proteins exploits the unnatural substrate 
tolerance of the native translational apparatus to accept amino acids analogues. 
Therefore, two basic requirements should be met in the method. One is to prepare a set of 
specific amino acid analogs, another is to create a targeted amino acids auxotrophic 
strains. Tirrell et al successfully incorporated azido-homoalanine into protein (mDHFR) 
with high translational efficiency. In this experiment, Methionine-tRNA synthetases was 
used to accept several methionine analogs to incorporate into protein, only azido-
homoalanine was recognized as a methionine surrogate and provided an opportunity to 
chemoselective modification and labeling of proteins in native conditions [84]. Except 
methionine, leucine [93], isoleucine [94], phenylalanine [95], tryptophan [96] and proline 
[97] auxotrophic strains have been investigated to incorporate UAAs into proteins. 
However, there are some basic issues to be addressed for ideal application. On one hand, 
the tolerance to analogs for an aminoacyl tRNA synthetase (aaRS) could be different and 
limited to further application. On the other hand, some amino analogs could be toxic to 
microorganisms and cause function loss of protein since they are faked to the living 
systems [98]. 
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1.4.1.2 Incorporation of UAAs by Nonsense Suppressor tRNAs 
Due to drawbacks in use of auxotrophic strains, UAAs incorporation into proteins 
by nonsense suppression has been used in attempts to replace a canonical amino acid with 
an analog and has proven to be a valuable tool for structure-function studies [99, 100]. In 
this strategy, the amber (UAG) nonsense codon was introduced to instead of the codon 
for the amino acid of interest.  Since aaRS does not cross-react with any of the 
endogenous tRNAs or any different aminoacyl tRNA synthetase, this replacement will 
not recognize any of the common.  As a result, desired amino acid will be recognized and 
insertion because of suppression of the nonsense codon with an aminoacylated tRNA 
[Figure 1.9]. Although it seems like a promising method to incorporate UAAs, its further 
application has been limited due to strict criteria to meet: the suppressor tRNA must have 
an efficient capacity to insert the UAAs and can not be recognized by any natural aaRS. 
Furthermore, only one stop codon can be used for suppression, incorporation of different 
UAAs into at one time becomes impossible [101]. 
 
Figure 1.9 Incorporating Unnatural Amino Acids into Proteins Using Nonsense Codon 
Suppression. Reproduced from [102] 
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1.4.1.3 Incorporation of UAAs through Frameshift Suppression 
To address those major disadvantages in the method of nonsense suppressor 
tRNAs, Sisido and coworkers have modified this method and successfully developed a 
remarkable approach for incorporation of UAAs, namely frameshift suppression, in 
which four-base codons have been created to assign non-natural amino acids within the 
framework of the existing three-base codon system.[103] Next, many more four-base 
codons such as pairs (AGGU, CGGU, CCCU, CUCU, and GGGU) have been examined 
and shown an high efficiency of 80% with respect to the wild-type protein [101]. Later, 
codons have even extended to five-base codons such as CGGN1N2, where N1 and N2 
could be one of four nucleotides and further expand the pool of codons for incorporation 
of UAAs [104].This strategy has been performed by using a unique tRNA/aaRS pair not 
only in E. coli but also in the eukaryotic cells such as the Xenopus oocytes [105]. 
Unfortunately, those efforts to perform frameshift suppression in Xenopus oocytes did 
not succeed because of poor suppression efficiency. To update, Dougherty et al 
appropriately designed two orthogonal frameshift suppressors (FS)-tRNAstwo tRNAs 
with 4-base anticodons, in which both can deliver UAAs in response to the quadruplet 
codons CGGG and GGGU. As a result, suppression efficiency was overcome by 
successfully reducing incorporation of undesired UAAs into proteins in a Xenopus 
oocyte [106]. This expanding size of codons makes it possible to incorporate several 
different UAAs into proteins at one time. 
 
1.4.1.4 Incorporation of UAAs by Creation of Unnatural Base Pairs 
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Creation of unnatural base pairs is another strategy for the extension of the 
genetic code. The most difficult challenge to expand size of codons is to synthesize novel 
unnatural base pairs that are orthogonal to the natural types. The first new base pair has 
been developed by Switzer et al. by creation of base pairs-isoC and isoG in 1989 [107]. 
The results confirmed that isoC and isoG base pair have been incorporated into DNA and 
that the protein has successfully expressed with an UAA in the help of a synthetic tRNA. 
Recently, a new non-natural named base-pyridine-2-one was developed by Hirao et al 
[108] and successfully incorporated into a mRNA in a DNA template. Several unnatural 
nucleotides base pairs with hydrophobicity has been created and used for incorporation of 
triphosphate [109]. However, in the strategy chemical reaction was used for synthesis of 
the mRNA and tRNA containing the non-natural bases; those unnatural base pairs must 
be orthogonal and be recognized by the DNA polymerase and RNA polymerase. Taken 
together, those factors above make it a long way to run before practical application. 
 
1.4.2 Applications of Unnatural Amino Acid Incorporation 
1.4.2.1 Identifying Structural and Functional Domains 
Unnatural amino acid mutagenesis as a tool to investigate various structural and 
functional protein domains has been studied extensively. For instance, cation-π 
interaction, as an important noncovalent binding interaction relevant to structural biology 
has attracted much attention [110, 111]. Particularly, cation-π interactions play a vital 
role in biological recognition, especially in the binding of acetylcholine biology. Zhong et 
al. explored this function by incorporating serial fluorine substitutions in Trp-149 of the 
muscle type nAChR via unnatural amino acid mutagenesis [112]. In this research, a 
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cation-π interaction between acetylcholine, a quarternary amine, with the ligand binding 
domain of the nAChR was confirmed and pointed out electrostatic potential of the 
tryptophan indole ring. Since lots of protein are supposed to have cation- cation-Π 
interaction, incorporation of unnatural amino acid could be very useful tool to explore 
this interactions. Also, the strategy of incorporation of UAAs has proven to be a powerful 
tool for investigating protein dynamics. For example, the incorporation of fluorescent 
side chains in an UAAs by using the nonsense suppression approach can monitor protein 
conformational change [100, 113]. Furthermore, two kinds of fluorescent side chains can 
be incorporated into one protein and provide an opportunity to explore cleavage of 
protein [114]. Additionally, the role of individual hydrogen bonds in protein stability and 
activity has been explored by incorporation of UAAs into proteins. A number of 
unnatural amino acids and amino acid analogs were synthesized and replaced alanine-82 
in T4 lysozyme to determine the effect of replacement on the stability of T4 lysozyme. 
The replacements of alpha, alpha-disubstituted amino acids, N-alkyl amino acids 
removed a hydrogen bond donor at those sites and reduced its stability and activity [115]. 
 
1.4.2.2 Inserting Functionalities into Proteins 
Incorporation of UAAs into proteins provides a powerful tool to engineer proteins 
with additional functionalities for special applications, especially for those functionalities 
that cannot be introduced translationally into large, interesting proteins. For instance, p-
carboxymethyl-L-phenylalanine can be incorporated into Tyr701 in human signal 
transducer and activator of transcription-1 (STAT1) instead of phosphotyrosine to 
improve resistant to hydrolysis by tyrosine phosphatases [116]. This directly introduce 
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modifications in proteins provides a certification for protein engineering to expand 
functions. Also, incorporation of UAAs into proteins has numerous applications in 
protein tagging and protein conjugation. Several kinds of methionine analogs containing 
azides into recombinant proteins for chemoselective modification have been incorporated 
into murine dihydrofolate reductase (mDHFR) [102]. This incorporation of UAAs 
containing azides provides very useful tool for a lots of application such as 
bioconjugation, in vivo imaging, protein labeling or drug design and delivery by 
Staudinger ligation and Click chemistry. For instance, site-specific PEGylation of human 
thrombomodulin has been performed to increase half-time in the blood via Staudinger 
ligation. [117]. An engineered LpIA acceptor peptide (LAP) with an alkyl azide have 
been developed and further labeled in living mammalian cells [118]. This strategy 
developed here provides an opportunity to biochemical and imaging studies of cell 
surface proteins. 
1.4.2.3 Studying Signal Transduction  
Incorporation of UAAs into proteins is becoming a powerful tool for investigating 
signal transduction pathways. A wide range of researches in vitro translation systems has 
been performed to explore and understand signal transductions in E.coli or yeast express 
systems by incorporation of UAAs. The protein phosphorylation is essential in regulating 
signal transduction cascades associated with cancer and other biological processes. 
Vázquez et al [119] studied phosphorylation dependent signaling by a series of 
phosphorylated residues prepared via incorporation of sensitive fluorescent amino acid 
DANA in the sequence RLYRpSLPA. The control of phosphorylation-dependent 
signaling has been achieved by the development of phosphorylated residues and provided 
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a useful tool to explore the role of protein phosphorylation in signal transduction 
cascades. 
 
1.4 Research Design and Rational 
Thromboembolic diseases such as myocardial infarction, stroke, and 
thromboembolism are severe with significant mortality and morbidity in the United 
States. Antithrombotic agents that prevent blood clotting can be used for both the 
prevention and treatment of active vascular thrombosis. However, current antithrombotic 
therapy is limited by the risk of series bleeding, hemorrhagic complication. A direct 
correlation exists between the intensity of anticoagulation and severity of bleeding. 
Recent advances in the molecular bases of haemostasis have highlighted new targets for 
novel antithrombotic agent design. Specifically, endothelial thrombomodulin (TM) plays 
a critical role in local haemostasis by binding thrombin and subsequently converting 
protein C to its active form (APC. In addition, the binding of thrombin to TM drastically 
alters the thrombin’s procoagulant activities to anticoagulant activities. Importantly, TM 
expression, however, decreases in perturbed endothelial cells, predisposing to thrombotic 
occlusion and particularly in response to a variety of inflammatory stimuli, direct vessel 
wall injury, and oxidant stress. TM is a type I membrane protein. The lipid bilayer in 
which it resides serves as an essential ‘cofactor’, locally concentrating and coordinating 
the appropriate alignment of reacting cofactors and substrates for protein C activation. 
Lipid membranes also play pivotal roles in activation of other anticoagulant enzymes. On 
the other hand, liposomes have been extensively studied as cell surface model as well as 
carrier for delivering certain vaccines, enzymes, drugs, or genes to the body. In this 
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study, we hypothesized that combination of antithrombotic membrane protein TM into 
lipid membrane mimetic assembly (liposome) through recombinant and bioorthogonal 
conjugation techniques provides a rational strategy for generating novel and potential 
antithrombotic agent (as shown in Figure 1.10). Namely, the liposomal TM conjugate 
mimics the native endothelial antithrombotic mechanism of both TM and lipid 
components and thus is more forceful than current antithrombotic agent. 
 
Figure 1.10 Schematic Illustration of Proposed Membrane Mimetic Re-expression of 
Membrane Protein onto Liposome. 
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CHAPTER II   
SURFACE FUNCTIONALIZATION OF LIPOSOME THROUGH STAUDINGER 
LIGATION 
(Partial results from Zhang, H. L., Ma, Y., Sun, X-L. Chem. Comm. 2009, 3032-3034)  
2.1 Introduction 
Liposome, a spherical closed self-assembled (phospho) lipids, has been 
extensively studied as model of cell membrane and mostly as carrier for drug/gene 
delivery applications [1, 2]. Liposome surface functionalization facilitates enormous 
potential application of liposomes [3, 4]. Cell surface carbohydrates is attractive model 
for liposome surface modification with oligosaccharides due to their protein-rejecting 
ability, biodegradability, low toxicity, and especially, cell targeting ability through 
specific binding interactions with receptors expressed at the targeted cells surface. For 
example, monosialoganglioside (GM1) can enhance circulation lifetimes of liposomes 
comparable to that observed for PEG [5]. Sialyl lewis X decorated liposome has been 
demonstrated to target delivery of drugs to endothelial cells based on the site-specific 
expression of E- and P-selectin on the blood vessel during inflammation [6]. On the other 
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hand, carbohydrate-decorated liposomes have been used as multivalent platform of 
carbohydrates to inhibit carbohydrate-mediated cell adhesion. For example, sialic acid-
decorated liposome showed strong inhibitory activity against influenza hemagglunitin 
and neuraminidase. 
 Conventional method to prepare surface functionalized liposome involves the 
initial synthesis of the key lipid-ligand conjugate, followed by formulation of the 
liposome with all lipid components. In this direct liposome formation method, some of 
the valuable ligands inevitably are facing the enclosed aqueous compartment and thus 
become unavailable for their intended interaction with their target molecules. Particularly, 
it is unrealistic if the targeting ligand is only available in minimum amount. Furthermore, 
lipid-ligand conjugates normally have limited solubility and stability in solvent, or are 
incompatible with various stages of manufacture. Alternatively, chemical modification 
methods, which in most cases involve the coupling of biomolecules to the surface of 
preformed vesicles that carry functionalized (phospho)lipid anchors, have been developed 
[8,9]. So far, variable success using amide [10] or thiol-maleimide coupling [11] as well 
as by imine [12] or hydrazone linkage [13] have been achieved. However, in many cases 
there is a lack of specificity resulting in the uncontrolled formation of the number of 
covalent bonds between liposome and biomolecules of interest. Most recently, copper (I)-
catalyzed [3+2] cycloaddition, namely “Click” chemistry, which can occur efficiently in 
aqueous media at room temperature and selectively between azide and alkyne [14] has 
been investigated as novel generic chemical tool for the facile in situ surface modification 
of liposomes [15]. However, the key limitation of the Click chemistry is the use of Cu (I) 
catalyst, which results in residual copper in the targeted liposome preparations and could 
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be a potential concern. Normally, it may be difficult to completely remove copper out 
from the resultant liposome [15] and thus it will affect the liposome’s biological 
application later on.  
The Staudinger ligation, in which an azide and triphenylosphine selectively react 
to form an amide has been used for chemical selective modification of recombinant 
protein under native condition [16]. Recently, Staudinger ligation has been successfully 
performed in living animals without physiological harm, suggesting the potential for 
applications in cell surface functionalization [17]. Particularly, the reaction is known to 
occur in high yield at room temperature in aqueous solvents and without any catalyst, and 
is compatible with the unprotected functional groups of wide range of biomolecules. 
Herein, we report an efficient and chemical selective liposome surface functionalization 
with lactose as model carbohydrate through Staudinger ligation (Figure 2.1). The high 
specificity and high yield as well as biocompatible reaction condition natures of the 
Staudinger ligation approach make it an attractive alternative to all current protocols for 
liposome surface functionalization. 
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Figure 2.1 Schematic Illustration of Liposome Surface Glyco-Functionalization through 
Staudinger Ligation. 
2.2. Experimental 
2.2.1 Materials and Methods 
All solvents and reagents were purchased from commercial sources and were used 
as received, unless otherwise noted. Deionized water with a resistivity of 18 Ω was used 
as a solvent in all polymerization reactions. 
Thin-layer chromatography (TLC) was performed on Whatman silica gel 
aluminum backed plates of 250 nm thicknesses on which spots were visualized with UV 
light or by charring the plate after dipping in 10 % H2SO4 in methanol. 
1
H NMR spectra 
were recorded at room temperature with a Varian INOVA 300 MHz spectrometer. In all 
cases, the sample concentration was 10 mg/mL, and the appropriate deuterated solvent 
was used as an internal standard. Dynamic Light Scattering was recorded with 90Plus 
particle size analyzer (BIC). Fluorescent spectrum was measured with FluoroMax-2 (ISA) 
 
2.2.2 Synthesis of DPPE-triphenylphosphine for Chemoselective Surface 
Functionalization via Staudinger Ligation 
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Figure 2.2 Scheme of Synthesis of DPPE-Triphenylphosphine 
2.2.2.1 Synthesis of 1-Methyl-2-Diphenylphosphinoterephthalate 
1-Methyl-2-Diphenylphosphinoterephthalate (2) Dry MeOH (3ml), triethylamine 
(TEA) (0.3 ml, 2 mmol), compound 1 (300 mg, 1.00 mmol), and palladium acetate (2.2 
mg, 0.010 mmol) were added to a flame-dried flask. The mixture was degassed in vacuo. 
While stirring under an atmosphere of Ar, and then diphenylphosphine (0.17 mL, 1.0 
mmol) was added to the flask with a syringe. The resulting solution was heated at reflux 
overnight, and then allowed to cool to room temperature and concentrated. The residue 
was dissolved in 250 mL of a 1:1 mixture of CH2Cl2/H2O and the layers were separated. 
The organic layer was washed with 1 M HCl (10 mL) and concentrated. The crude 
product was dissolved in a minimum amount of methanol and an equal amount of H2O 
was added. The solution was cooled to 4 °C for 2 hrs and the resulting solid was collected 
by filtration. The pure product 3 was isolated as 245 mg (69 %) of a golden yellow solid, 
mp 183–185°C. 1H NMR (400 MHz, CDCl3): 3.75 (s, 3H), 7.28–7.35 (m, 11H), 7.63–
7.67 (m, 1H), 8.04–8.07 (m, 1H). 
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2.2.2.2 Synthesis of 1-Succinimidyl 3-Diphenylphosphino-4-
Methoxycarbonylbenzoate 
1-succinimidyl 3-diphenylphosphino-4-methoxycarbonylbenzoate (4) 3, 3-
diphenylphosphino-4-methoxycarbonylbenzoic acid (216mg, 0.593mmol), 
dicyclohexylcarbodiimide (DCC) (129mg, 0.623mmol), and N-hydroxysuccinimide 
(NHS) (72 mg, 0.623 mmol) were dissolved in diethyl ether (20 mL) under Ar and stirred 
overnight at room temperature. After the diethyl ether solvent was evaporated, the yellow 
crystalline product was isolated by filtration. Recrystallization from 2-propanol (20 mL) 
yielded 164 mg (60 %) of 3 as yellow crystals. 
1
H NMR (CDCl3, 400 MHz) (ppm):  8.15 
(s, 2H), 7.67 (d, 1H, J ), 7.39-7.22(m, 10H), 3.75 (s, 3H), 2.82 (s, 4H, COCH2CH2CO); 
13
C NMR (CDCl3, 75 MHz) δ169.4 (COCH2CH2CO), 166.7, 161.5, 143.0, 142.6, 140.1, 
139.9, 137.0, 136.8, 136.6, 134.5, 134.2, 131.3, 130.2, 129.6, 129.2, 129.1, 128.1, 53.0, 
26.0 (COCH2CH2CO); 
31
P NMR (CDCl3, 121 MHz), δ (ppm): -3.05 
 
2.2.2.3 Synthesis of DPPE-Triphenylphosphine 
DPPE (0.26 g, 0.376 mmol) was dissolved in 40 mL CH2Cl2, and 0.8 mL Et3N 
was added. After stirring for 30 mins at room temperature, a solution of Succinimidyl 3-
Diphenylphosphino-4-methoxycarbonylbenzoate (4) (0.23 g, 0.500 mmol) in 50 mL 
CH2Cl2 was added. The reaction mixture was stirred at room temperature for 24 hrs and 
then concentrated. The crude product was purified by TLC using chloroform/methanol (4: 
1) to afford 5 (0.283g, 73%).  
1
H NMR (CDCl3, 400 MHz) δ (ppm): 
31
P NMR (CDCl3, 
121 MHz), δ(ppm) 
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2.2.3 Preparation of Unilamellar Liposome for Surface Functionalization 
DPPC (30mg, 40.87 µmol), cholesterol (8mg, 20.4 µmol), DPPE-
triphenylphosphine (3.5 mg, 3.2 µmol) (2: 1: 5 % molar ratio) were dissolved in 3.0 mL 
chloroform. The lipid mixture was dried onto the wall of a 50 mL round-bottom flask and 
the solvent was gently removed on an evaporator under reduced pressure to form a thin 
lipid film on the flask wall and kept in a vacuum chamber overnight. Then, the lipid film 
was swelled in the dark with 2.5 mL PBS buffer (pH 7.4) containing 85 mM 
Carboxyfluorescein (CF) to form the multilamellar vesicle suspension. Followed to be 
subjected 10 freeze-thaw cycles involving quenching in liquid N2 and then immersed in a 
50 ℃ water-bath. The crude lipid suspension thus formed, followed by extruded through 
polycarbonate membranes (pore size 2000 nm, 600 nm, 200 nm, 100 nm gradually) to 
obtain the vesicles (LUVs) with approximately uniform diameter (110±5 nm). Separation 
of the CF vesicles from non-entrapped CF was achieved by gel chromatography, which 
involved passage through a 1.5×20 cm Column of Sephadex G-50), about 6ml liposome 
were gained. 
 
2.2.4 Lactose Coupling to Performed Liposome via Staudinger Ligation 
To the liposome made in the part of preparation, added 4 mg azido-lactose in 0.2 
mL PBS buffer (Argon bubble before use) into 2 mL liposome. The Staudinger ligation 
was run at room temperature for 6h under an argon atmosphere, then the unreacted azido-
lactose was removed by gel filtration (1.5×20 cm Column of Sephadex G-50). The 
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stability of liposome was monitored by FluoroMax-2 (ISA). The size of liposomes in the 
Staudinger ligation was monitored over time by using 90Plus particle analysizer.  
 
2.2.5 Determination of Lactose Density on the Surface of Liposome 
The liposomes (5 mg/mL, total lipid concentration) separated from the column 
was divided into two parts, one part was for reaction with lactose-azide, another was for 
control.  
Assay: 20 µL reaction solution and 1980 µL PBS were mixed, and then diluted 
into 10 times. 
Control: 20 µL original solution (5 mg/mL) and 1980 µL PBS were mixed and 
then diluted into 10 times. 
Standard curves of lactose assay: The method is that described by Dubois et al. 
with some modifications. To 0.5 ml of lactose solution (20 μg/mL, 40 μg/mL, 60 μg/mL, 
80 μg/mL, 100μg/mL, respectively), 0.5ml of 5% phenol solution was added and mixed. 
Then 2.5 mL concentrated H2SO4 was added directly into the solution with 1-2 s. The 
mixture was then vortexed, and allowed to stand for 30 mins at room temperature. 
Readings were taken at 490 nm against a blank prepared by substituting distilled water 
for the lactose solution (Figure 2.3). 
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Figure 2.3 Standard Curves of Lactose Assay 
Colorimetric analysis: To 0.5 mL of liposome with immobilized lactose, 0.5ml of 
0.5 % phenol solution was added and mixed. Then 2.5 mL concentrated H2SO4 was 
added directly into the solution with 1-2 s. The mixture was then vortexed, and allowed 
to stand for 30 mins at room temperature. Readings were taken at 490 nm. The amount of 
lactose from calibration curve was calculated. 
 
2.2.6 Assay for Coupling Accessibility of Functionalized Liposome 
To detect the lactose in the liposome, 0.5 mL PBS buffer (pH 7.4) including 0.5 
mg lectin was added into 100 µL liposome conjugating the lactose. In the reaction, the 
size of liposomes and stability of liposome in the reaction were monitored over time (0h, 
1 h, 2 h, 3 h, 4 h), and a control was performed at the same conditions, too. 
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2.2.7 Evaluation of Stability of Functionalized Liposome by Dynamic Light 
Scattering and Florescence Assay 
The stability of liposome was also monitored by measurement of fluorescent 
leakage using FluoroMax-2 (ISA). 20 µL reaction solution and 1980 µL PBS were mixed, 
and then diluted into 10 times. The fluorescent intensity was measured by using 
FluoroMax-2 (ISA). Control experiment was conducted in the absence of azide-lactose.  
5, 6-carboxyfluorescein (CF) released from liposomes in PBS (pH 7.4) buffer at 
room temperature was measured over time. The excitation and emission wavelengths of 
5, 6-CF were 497 and 520 nm, respectively. The variation of the fluorescent intensity 
with release time was calculated according to the equation below  
Fraction of CF remaining in liposomes) = 1 - F/F0 
where F is the fluorescent intensity measured at any time during the experiment and F0 is 
the total fluorescent intensity measured after disrupting liposomes completely with 0.5% 
Triton X-100 in PBS (pH 7.4) buffer. 
Liposome size and distribution were analysized by dynamic/static light scattering 
with 90Plus particle size analyzer (BIC). 
 
2.3 Results and Discussion 
2.3.1 Characterization of DPPE-Triphenylphosphine 
As a proof-of-concept, we have explored the possibility to prepare glycosylated 
liposomes by coupling unprotected lactosyl derivative carrying an ethyl spacer 
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functionalized with an azide group to the surface of liposomes that incorporate synthetic 
anchor lipids carrying a terminal triphenylosphine via Staudinger ligation. First, the 
terminal triphenylosphine carrying anchor lipid 5 was synthesized by amidation of 
commercially available DPPE with 3-diphenylphosphino-4-methoxycarbonylbenzoic 
acid NHS active ester 4, which was prepared according to the procedure described by Ju 
et al. [18] (Figure 2.4). However, it was found that an unwanted oxidation product, 
triphenylosphine oxide 3 easily formed during crystallization purification of 
triphenylosphine 2 by using aqueous methanol. The oxidized compound 3 was confirmed 
by comparing with oxidation product of triphenylphosphine 2 with hydroperoxide in 
methanol, which give a typical chemical shift at 34.2 ppm of phosphine oxide, while the 
phosphine in 2 gives a chemical shift at -3.74 ppm in 31P NMR spectrum (Figure 2.3A). 
Fortunately, the phosphine oxide 3 can be converted back to phosphine 2 by reduction 
with trichlorosilane in toluene in high yield [19]. There is no oxidized product formed 
during DPPE-triphenylosphine 5 synthesis and purification when organic solvents are 
used. With this oxidation in mind, the stability of the intermediate triphenylosphine 2 and 
the targeted lipid triphenylosphine conjugate 5 were monitored with 
31
P NMR. As results, 
the oxidation of phophine 2 and 5 in organic solvent such as chloroform are very slow 
(Figure 2.4B and 2.4C). Mass Spectrometry has been used to confirm its molecule weight 
(1036) (Figure 2.4D) 
A                    B                             C                            D 
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Figure 2.4 TLC traces and 
31
P NMR Study of Triphenylphosphine Derivatives 
 
2.3.2 Integrity Assay of Liposome in and after Coupling Reaction 
With the anchor lipid DPPE-triphenylosphine 5 in hand, next, small unilamellar 
liposomes composed of saturated phospholipids (DPPC) and cholesterol (2: 1 molar 
ratio) and 5 mol % of the anchor lipid 5 were prepared by extrusion through 
polycarbonate membranes with pore size of 600 nm, 200 nm, and 100 nm sequentially at 
65 ℃. This produced predominately small unilamellar vesicles with an average mean 
diameter of 120 ± 5 nm as determined by dynamic light scattering (DLS). Next, 
conjugation of azide-containing lactose ligands [20] to the preformed liposomes was 
performed in PBS buffer (pH 7.4) at room temperature under an argon atmosphere for 6 
hrs (Figure 2.1). DLS was used to verify the integrity of the vesicles during and after the 
coupling reaction. As shown in Figure 2.5, there is no significant change in the size of the 
vesicles during and after conjugation reaction. Therefore, the reaction conditions 
described above do not alter the integrity of the liposomes. 
A                                                                 B  
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Figure 2.5 Dynamic light scattering monitoring of liposome, A: before conjugation, B: 
after conjugation 
Next, to test whether the experimental conditions used for the conjugation 
reaction could provoke some leakage of the liposomes, we have exposed our standard 
conditions to the same type of liposomes having encapsulated self-quenching 
concentrations of 5, 6-carboxyfluorescein [21]. Based on the fluorescence quenching 
determinations (Figure 2.6), we could demonstrate that no apparent leakage was triggered 
by the conjugation reaction compared to the liposomes incubated in the absence of the 
coupling reagents. Therefore, the conjugation conditions established here are harmless for 
liposome surface functionalization. 
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Figure 2.6 Kinetics of carboxyfluorescein release from liposome in the presence of 
lactose-azide (A) and in the absence of lactose-azide (control experiment) (B). Insert 
shows the changes of fluorescence intensity of liposomes suspension of reaction and 
control during conjugation and final decomposition with surfactant. 
 
2.3.3 Quantification of Lactose on the Surface of Liposome 
Furthermore, the grafted carbohydrate on the surface of liposome was quantified 
by the phenol-sulfuric acid method [22]. Briefly, phenol solution was added to a solution 
of liposome with conjugated lactose, and mixed. Then concentrated H2SO4 was added 
directly into the solution. The mixture was then vortexed, and allowed to stand for 30 
mins at room temperature. The optical density was then recorded at 490 nm. Considering 
that about 40 % of the triphenylosphine anchor is oriented toward the interior of the 
vesicles, 80 % of the out-oriented triphenylosphine have been modified in this Staudinger 
ligation modification. 
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2.3.4 Assay for Coupling Accessibility of Functionalized Liposome 
To determine whether the grafted lactose residues are easily accessible at the 
surface of liposomes, lectin binding assay was conducted by incubating lactosylated 
liposome in the presence of galactose binding lectin (Arachis hypogae, 120 kDa, Sigma) 
in PBS (pH 7.4). After 30 mins, apparent visible aggregation formed and was monitored 
in DLS experiment (Figure 2.7A). In contrast, neither aggregation nor size change was 
observed with control liposomes without lactose. Furthermore, the presence of free 
lactose (5.0 mM) prevented aggregates formation (not shown), confirming that the 
agglutination was due to a specific recognition of the lactose residues on the surface of 
the liposomes by lectin in multivalent interactions (Figure 2.7B). 
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Figure 2.7 Agglutination glycosylated liposome with lectin via multivalent interaction 
(A) and monitored with DLS (B) 
 
2.3.5 Evaluation of Stability of Functionalized Liposome 
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The stability of liposomes over time is an important concern in drug/gene delivery 
application. It is known that monosialoganglioside (GM1) could enhance circulation 
lifetimes of liposomes comparable to that observed for PEG. In this study, the stability of 
the lactosylated liposome was evaluated by comparing with liposome without lactose at 
room temperature as monitored with DLS. As shown in Figure 5, both liposomes showed 
good stability during the eight days period. However, the liposome without lactose began 
to collapse and aggregate since 9th day (Figure 2.8A), while there were no apparent size 
change for the lactosylated liposome (Figure 2.8B). This result demonstrated that the 
presence of lactose on the liposome surface provides a stereic barrier that prevents 
liposome aggregation. 
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Figure 2.8 Stability of liposome without lactose (A) and liposome with lactose (B) 
monitored with DLS 
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2.4 Conclusion 
In conclusion, we have developed an efficient and chemoselective conjugation 
method for liposomes surface glyco-functionalization based on Satudinger ligation. The 
reaction could be performed under mild conditions in aqueous buffers without catalyst 
and in high yields under reasonable reaction times. The reaction conditions developed in 
the present work did not alter the integrity of the bilayers, in terms of liposome sizes and 
leakiness, and provided perfectly functional vesicles. This versatile approach, which is 
particularly suitable for the ligation of water soluble molecules and which can 
accommodate many chemical functions, is anticipated to be useful in the coupling of 
many other ligands onto liposome. 
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CHAPTER III  
INCORPORATION OF UNNATURAL HOMOANALINE INTO  
RECOMBANANT THROMBOMODULIN FOR SITE SPEIFIC CONJUGATION 
(Protocol modified from Cazalis, C. S., Haller, C. A., Sease-Cargo, L., Chaikof, E. L.  
Bioconjug. Chem. 2004, 15, 1005–1009) 
3.1 Introduction 
Thrombomodulin (TM) is an endothelial anticoagulant protein that contributes to 
local hemostatic balance by modulating the activity of thrombin from a procoagulant to 
an anticoagulant protease [1–3]. Through binding with thrombin to form complex on the 
endothelial surface, TM removed thrombin’s procoagulant properties by stopping 
cleavage of fibrinogen or activation of platelets. At the same time, the TM-thrombin 
complex involves in protein C activation pathway in which protein C is bound to TM-
thrombin complex to immediately enhance activation over 1,000 fold. Subsequently, the 
activated form of protein C (APC), an anticoagulant protease, selectively inactivates 
coagulation factors Va and VIIIa, providing an essential feedback mechanism in 
preventing excessive coagulation. TM has been considered as one of key factors 
contributing to thrombotic regulation [4]. It also has been reported that reduction in TM 
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activity, induced by a targeted point mutation or injection of anti-TM antibodies in mice, 
makes the animals more susceptible to thrombogenic challenges [5, 6]. Administration of 
exogenous recombinant TM to these animals has shown antithrombotic effects.  In the 
past decades, various recombinant TM proteins consisting of extracellular portions have 
shown potential anticoagulant activity [7–12]. One such example is recombinant human 
soluble TM α (rhsTMα or ART-123), which was used in Japan to treat patients with 
disseminated intravascular coagulation (DIC) [12, 13]. 
The structure of TM and its structural domains necessary for activation of protein 
C have been resolved.  The fifth and sixth EGF domains of TM represent the binding site 
of thrombin, while the fourth EGF domain is responsible for protein C activation, all 
which are related to TM’s anticoagulant activity [2, 3]. However, TM’s third EGF-like 
domain is of equal importance in the thrombotic cascade accelerating the proteolytic 
activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin [14] 
Activated TAFI (TAFIa) cleaves C-terminal lysine and arginine residues from partially 
degraded fibrin. The removal of these positively charged residues suppresses the ability 
of fibrin to catalyze plasminogen activation and thereby delays clot lysis [15]. Therefore, 
recombinant TM containing all extra cellular portions of TM simultaneously functions as 
a procoagulant and anticoagulant which would be reasonably ineffective as an 
anticoagulant therapeutic. Consequently, recombinant TM containing the EGF-like 
domains 456 (rTM456) is the only engineered TM recombinant considered to be a 
potential candidate as a pure anticoagulant [16–19]. The smaller protein fragment, from a 
bioengineering standpoint, provides an opportunity through manipulation and 
modification to optimize and generate a feasible biotherapeutic. 
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Incorporation of unnatural amino acids to proteins has become a very popular tool 
to expand protein’s functions and shown its promising potential in chemical biology and 
pharmaceutical industry. To date, lots of methods have been explored to study 
incorporation of unnatural amino acids for widely applications such as protein-protein 
interaction, biophysical probes and creation of functionality [20]. Since Levine et al. [21] 
firstly introduced auxotrophic bacterial strains for incorporation of unnatural amino acids, 
this strategy has been studied extensively and become commercially available to 
numerous biology studies. In this strategy, the native translational apparatus recognized 
analogs of natural amino acids to provide an opportunity to accept unnatural amino acid 
analogues for incorporation to protein. Kiick et al. [22] successfully incorporated azido-
homoalanine into protein (mDHFR) with high translational efficiency under help of 
Methionine-tRNA synthetases for acceptance of methionine analogs. To only incorporate 
azido-homoalanine into protein, natural methionine was removed from media to exclude 
side incorporation of methionine. This study developed here provided an opportunity to 
chemoselective modification and labeling of proteins in native conditions. In this study, 
we propose that the insertion of homoalanine into protein TM containing the EGF-like 
domains 456 (rTM456) by auxotrophic E.Coli strain to attain an optimal platform for 
exploring site specification modification of recombinant TM (Figure 3.1). 
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Figure 3.1 Schematic Structure of the Site-Specific Azide Functionalized Consecutive 
EGF-like Domains 4-6 of Human TM with His-Tag and S-Tag 
 
3.2 Experimental 
3.2.1 Materials and Methods  
All solvents and reagents were from commercial sources and were used as 
received, unless otherwise noted. Deionized water was used as a solvent in all 
experiments. Human thrombomodulin cDNA clone was from ATCC (Manassas, VA), 
pET Dsb Fusion System 39b, competent cells, and kanamycin sulfate were from EMD 
Chemicals (Philadelphia, PA).  Phusion® High-Fidelity PCR Kit, BamHI-HF, KpnI-HF, 
T4 DNA ligase and alkaline phosphatase were from New England Biolabs (Ipswich, 
MA). All plasmid purification kits were from QIAGEN Inc. (Chatsworth, CA).  E. coli 
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strain B834 (DE3), plasmid pET-39b(+), and Site-Specific Enterokinase Cleavage and 
Capture  kits were from Novagen (Madison, WI).  The mouse monoclonal antibody 
specific to human TM was from COVANCE Corp. (Richmond, CA).  Synthetic 
oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville, 
IA). Purified recombinant human PC and human thrombin were from Haematologic 
Technologies Inc. (Essex Junction, VT).  Human anti-thrombin, recombinant human TM 
and chromogenic substrate Spectrozyme PCa were from American Diagnostica Inc. 
(Stamford, CT). L-azidohomoalanine was from AnaSpec Inc. (Fremont, CA). Imidazole, 
sodium azide, other chemicals were from Sigma-Aldrich (USA).  Fluorescence imaging 
of SDS-PAGE gels was performed using a Typhoon 9410 Variable Mode Imager 
(Amersham Biosciences, USA). Dialysis was performed using cellulose membranes with 
a molecular weight cutoff of 3.5 kDa with water as solvent. OD value was recorded on a 
Varian Bio50 UV-vis spectrometer.  
 
3.2.2 Construction of Mutant of TM EGF-like (4-6) Domain 
Plasmid Constructs. Recombinant thrombomodulin EGF456 was prepared by 
expressing plasmid TM456-N3 in E. coli methionine auxotroph B834 (DE3). To encode 
thrombomodulin EGF 4-6 domains, forward primer: 5' CGC GGA TCC CGA CCC GTG 
CTT CAG A 3' and reverse primer: 5' GTT GCA AAA CAG CTG GCA CCT GTG 3' 
were used to create a mutant with C terminal methionine based on human 
thrombomodulin cDNA, in which unnatural amino acid could be incorporated into 
recombinant proteins to provide an azide group for chemoselective modification. To 
remove extra methionine in other sites of the mutant and to improve resistance to 
  69 
oxidative inactivation and enzymatic activity, a point mutation was created to switch 
methionine to leucine at position 388 by using forward primer 5’ CAC AGG TGC CAG 
CTG TTT TGC AAC 3' and reverse primer 5' CGC GGA TCC GAT TAC ATA CC C 
CCC AC 3'.  PCR fragments containing the mutant sequences were ligated into pET 39 
b(+) to make the expression plasmid TM456GGM. The sequence of each mutant plasmid 
was confirmed by DNA sequencing. 
 
3.2.3 Incorporation of Azides into TM456 in E.coli and Protein Extraction  
Media and materials for E. coli culture were prepared as following: 
Table I. Media A for Single Colony Culture (10ml) 
Materials Volume Sterilization 
M9 medium (1 x) 10 mL autoclave 
MgSO4 (1 M)  10 µL 0.22 μm Filter 
CaCl2 (1 M) 1 µL 0.22 μm Filter 
20% D (+) Glucose 200 µL 0.22 μm Filter 
Thiamine Hydrocloride (1 mg/mL) 10 µL 0.22 μm Filter 
19AA W/O Methionine 400 µL 0.22 μm Filter 
L-Methionine solution (20 mg/mL) 20 µL 0.22 μm Filter 
Kanamycin (35 mg/mL) 10 µL 0.22 μm Filter 
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Table II. Media B for Scale Up Culture (1 L) 
Materials Volume Sterilization 
M9 medium (5 x) (autoclave) 200 mL autoclave 
dH2O 720 mL autoclave 
MgSO4 (1 M) 1 mL 0.22 μm Filter 
CaCl2 (1 M) 100 µL 0.22 μm Filter 
20% D (+) Glucose 20 mL 0.22 μm Filter 
Thiamine Hydrocloride (1 mg/mL) 1 mL 0.22 μm Filter 
19AA W/O Methionine 40 mL 0.22 μm Filter 
L-Methionine solution (20 mg/mL) 1 mL 0.22 μm Filter 
Kanamycin (35 mg/mL) 1 mL 0.22 μm Filter 
 
The recombinant TM456-N3 was expressed in E. coli as the following procedure: 
1. Transform the constructed TM456GGM to the appropriate E. coli strain and plate 
out on minimal medium plates. Incubate the plates overnight at 37°C.  
2. Pick one colony and use it to inoculate 10 mL Media A. Incubate the culture on 
orbital incubator (180 rpm) overnight at 37°C. 
3. Add the overnight culture to 1 L medium B plus 2mL L-Methionine (20 mg/mL) 
and incubate the culture at the appropriate temperature for induction until the 
absorbance at 600 nm is 0.8. 
4. Centrifuge the cell suspension for 5 mins at 4,500 rpm at 4°C. 
5. Washing cell pallets with 1 × M9 solution (autoclave)  
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6. Centrifuge for 5 mins at 4,500 rpm at 4 °C. Repeat 2 more times 
7. Resuspend the pellet in 1 L Medium B (without methionine) and incubate for 1 hr 
at 37 °C to  starve the cells 
8. Add 2 mL Azidohomoalanine (20 mg/mL) and incubate for a further 30 mins. 
9. Induce expression of the target protein by adding 1.2 mL IPTG (500 mM) to the 
medium and incubate the culture at 25 °C overnight. 
10. Centrifuge the cell suspension for 10 mins at 8000 x g at 4 °C. 
11. Store the cell pellet at -20 °C or -80 °C when not immediately used. 
In the expression of rTM456-N3, a culture lacking methionine served as the 
negative control. After cells were harvested by centrifugation for 30 mins at 4 °C, lysis 
buffer (20 mM Tris-HCl, pH 8.0, and 300 mM NaCl) with the protease inhibitor PMSF 
(10 µg/mL) was added to a total volume of 50 mL. The cells were then sonicated every 2 
min with a probe sonicator (Sonifier 450, Branson Ultrasonics, CT) on ice. Cell 
disruption was evidenced by partial clearing of the suspension. Then the broken cells 
were centrifuged 15000 x g for 30 mins and the supernatant was collected and directly 
applied to an immobilized metal affinity column (HisTrap FF) equilibrated with washing 
buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, and 20 mM imidazole). The column 
was washed with 10 column volumes of washing buffer, after which the column was 
flushed with 3 column volumes of cleavage buffer (20 mM Tris-HCl, pH 8.0, 300 mM 
NaCl, and 250 mM imidazole) to afford His-rTM456-N3. Finally, enterokinase was used 
for site-specific cleavage to remove the fusion tag and generate the target protein rTM456-
N3. 
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A similar procedure was used for preparing positive control protein His-rTM and 
rTM456 without incorporation of azide group. Briefly, the expression plasmid TM456GGM 
was transformed into E. coli BL21 (DE3) cells. Bacteria were grown in LB media under 
the same conditions. rTM purification and fusion tag removal were performed under the 
same conditions. 
 
3.2.4 Western Blot for Identification of rTM456 
After purification rTM456 from HisTrap FF and followed by cleavage by 
enterokinase, SDS-PAGE gel electrophoresis was used to separate recombinant TM456 
with his tag and recombinant TM without his tag. 12 % Tris–glycine gels was made in 
the lab and used throughout. Electrophoresis was performed on XCell SureLock™ Mini-
Cell Electrophoresis System (Invitrogen). The running buffer is 1X tris-glycine-SDS 
buffer. 20 µL solution was loaded into wells for each sample. Electrophoresis was run at 
120 V for 2 hrs.   After the gel has run, samples were transfer to nitrocellulose membrane 
at 90 V for 45 mins. The mouse monoclonal antibody specific to human TM was for 
binding of rTM. ECL kit (GE Healthcare) was use for detection of proteins. 
 
3.2.5 Mass Spectrometry Analysis of Recombinant TM456  
After electrophoresis, the gels immediately was rinsed in dH2O, and then 
immersed into Zinc-imidazole staining buffer (Bio-rad). After staining, the gel was rinsed 
completely in dH2O. Then protein bands was cut from gel and destained according to 
standard protocols as instruction. Next, 2 or 3 pieces of gels were crushed and immersed 
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into 1mL extraction buffer (Formic acid/ water/2-propanol (1:3:2 v/v/v) (FWI) for 2hrs. 
Then samples were centrifuged at 15, 000 rpm for 20 mins. The supernatant was 
collected for MALDI-TOF analysis. 
The extraction solution was lyophilized and a MALDI matrix solution (FWI 
saturated with 4-hydroxy-a-cyano-cinnamic acid (4HCCA)) was added to redissolve and 
prepare the protein for MS analysis using the dried-drop method of matrix crystallization 
[23]. The MALDI MS experiments were carried out on a Bruker Ultraflex III tandem 
time-of-flight (TOF/TOF) mass spectrometer (Bruker Daltonics, Billerica, MA), 
equipped with a Nd:YAG laser emitting at a wavelength of 355 nm. All spectra were 
measured in positive reflector mode. The instrument was calibrated externally with a 
poly(methyl methacrylate) standard prior to each measurement. Five different matrices 
were used: dithranol (DIT), 2,5-dihydroxybenzoic acid (DHB), and trans-2-[3-(4-tert-
butylphenyl)-2-methyl-2-propenylidene] malononitrile (DCTB) dissolved in 
tetrahydrofuran (THF) at 20, 10, and 20 mg/mL, respectively, as well as 3-hydropicolinic 
acid (HPA) and R-cyano-4-hydroxycinnamic acid (CHCA) dissolved in 
acetonitrile(ACN)/water (v/v, 50/50) at 5 mg/mL. Samples were prepared by sandwich 
method involving depositing 0.5 μL of matrix solution on the wells of a 384-well ground-
steel plate, allowing the spots to dry, then depositing 0.5 μL of each sample on top of a 
dry matrix spot, and adding another 0.5 μL of matrix solution on top of the dry sample 
(sandwich method). MALDI experiments were performed using Bruker’s LIFT mode. 
Data analysis was conducted with the flexAnalysis software. 
 
3.2.6 Availability of Azide Moiety in the Recombinant TM456  
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Samples of His-rTM456-N3 and rTM456-N3 were incubated with cyclooctyne 
functionalized Fluorescent dye Alexa Fluor® 647 DIBO (10 equiv, Invitrogen) in a 
phosphate buffer (pH 7.0) for 1 hr at room temperature. Then samples were dialyzed in 
Tris-HCl (20 mM, pH 7.4) for overnight. Next, samples were load into 12% tris-glycine 
gel for separation and carried out at 120 V for 1.5 hrs. Coomissee blue was used to stain 
gel. rTM456 without azide was used as a negative control and subjected to the same 
reaction conditions. Finally, an imaging system (Typhoon 9410 Variable Mode Imager, 
Amersham Biosciences, USA) was used to analysize the fluorescent labeled proteins on 
the gel. 
 
3.2.7 Cofactor Activity Assay of rTM 
The activity of rTM456 was defined as moles of produced APC per min by given 
amounts of rTM456 protein in the presence of thrombin. All activations of protein C by 
rTM conjugates were performed for 60 min in 20 mM Tris-HCl buffer, pH 7.4, 100 mM 
NaCl, 0.1% BSA, and 5 mM Ca
2+
 at 37°C.  
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37 ℃, 60 mins 
 
37 ℃, 5 mins 
 
37 ℃, 10 mins 
 
                                                             
Assay by APC Calibration Curve 
Figure 3.2 Flow Chart for Cofactor Activity Assay of TM  
Thrombin (10 nM): 10 µL 
TM or TM mutant (1 nM): 10 µL 
Protein C (5 µM):10 µL 
Buffer (Tris-HCl, BSA 0.1 %, Ca 
2+
 2.5 mM, pH 7.4): 70 µL 
Antithrombin III (90 µg/µL): 3 µL 
Heparin (2500 IU/mL): 2 µL 
PCa (4.4 mM): 5 µL (0.2 mM) 
final) 
Acetic Acid (20 %): 200 µL 
Buffer (Tris-imadole, pH 7.4): 700 µL 
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Typically, 20 nM thrombin and different rTM concentrations (1, 1.5, and 2 nM) 
were incubated in the assay buffer. After 60 mins, 3 µL antithrombin III (90 µg/µL) and 2 
µL heparin (2500 IU/mL) were added into the solution to stop the reaction. The inhibition 
of protein C activation was completed within 5 mins at room temperature. The produced 
APC was measured through hydrolysis of a chromogenic substrate (Spectrozyme PCa) by 
comparing a standard curve (Figure 3.3), in which the concentration of APC to the rate of 
p-nitroanilide (pNA) formation was measured. The hydrolysis of Spectrozyme PCa was 
performed for 10 mins in the assay buffer at 37 °C, in which pNA was produced and the 
concentration measured by monitoring at λ = 405 nm with a spectrophotometer. 
 
Figure 3.3 Standard Curve of Activated Protein C Assay 
 
3.3 Results and Discussion 
3.3.1 Construction of TM Mutant with Leucine Mutagenesis 
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A truncated TM fragment containing EGF4-6 with the insertion of a C-terminal 
non-natural methionine analogue was chosen as our target antithrombotic protein for site-
specific conjugation [19]. Specifically, a truncated recombinant TM mutant containing 
amino acid sequences 349-492 with a Met-388-Leu substitution and a C-terminal linker 
GlyGlyMet-N3 was constructed using site-directed mutagenesis (Figure 3.1).   
In the construction of plasmid, two mutant fragments were created for 
mutagenesis from methonine to leucine by point mutation. This mugagenesis here could 
improve resistance to oxidation by using leucine instead of methionine at 388 [24]. The 
first fragment from Asp to inserted leucine has 118 base pairs; while the second 
fragments from leucine to methonine in the terminal has 323 base pairs. The sizes of 
those fragments have been confirmed by DNA analysis on agarose electrophoresis 
(Figure 3.4).  
 
Figure 3.4 DNA Gel Analysis for Fragment: marker (lane 1), the fragment from Asp to 
inserted leucine (lane 2), from leucine to methonine (lane 3) and whole mutant (lane 4) 
After construction of TM456GGM, it was transformed into competent cells. Then, 
quantities of DNA encoding EGF-like 4-6 domain with a mutation of leucine at 388 have 
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been expressed in E. coli and harvested for DNA sequencing. The sequence of each 
mutated gene determined by DNA sequencing was following and was matched with its 
DNA sequence (marked by red and underline) as designed. 
MKKIWLALAGLVLAFSASAAQYEDGKQYTTLEKPVAGAPQVLEFFSFFCPHCYQ
FEEVLHISDNVKKKLPEGVKMTKYHVNFMGGDLGKDLTQAWAVAMALGVEDK
VTVPLFEGVQKTQTIRSASDIRDVFINAGIKGEEYDAAWNSFVVKSLVAQQEKAA
ADVQLRGVPAMFVNGKYQLNPQGMDTSNMDVFVQQYADTVKYLSEKKGSTSG
SGHHHHHHSAGLVPRGSTAIGMKETAAAKFERQHMDSPDLGTDDDDKSPGFSST
MAIDPDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHEPHRCQLFCNQTACPAD
CDPNTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSAL
ARHIGTDCDSGKVDGGDSGSGEPPPSPTPGSTLTPPAVGGM 
 
3.3.2 Mass Spectrometry Characterization of rTM456 
In this study, recombinant TM456 with His-tag and S-tag at the N-terminal and an 
azidohomolananine at the C-terminal was expressed in E. coli. Protein expression was 
confirmed by MALDI-TOF mass spectrometry (Figure 3.5). Other than Commisse blue, 
zinc –imidazole was used for protein staining. This staining method for protein detection 
is reversible and suitable for intake protein identification. Compared to other stains, it 
yields good efficiency and intact protein without need of digestion.  The measured values 
fit for calculated molecular mass of His-rTM-N3 (43192 D) and rTM-N3 (16645 D). 
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Figure 3.5 Mass Spectrometry for Characterization of His-rTM-N3 and rTM-N3 
 
3.3.3 Availability of Azide Moiety in the Recombinant TM 
The recombinants were further analyzed by SDS-PAGE and visualized by 
Coomassie blue staining (Figure 3.6A). The target recombinant TM fused to the leader 
sequence was clearly detected in the positive control cultures supplemented with 
azidohomoalanine, whereas it was not observed in the negative control culture. The 
recombinant TM with His-S tags was purified from the cell pellet by using metal-affinity 
chromatography with stepwise imidazole-gradient elution under native conditions. The 
rTM456-N3 was characterized by identification of a band at ~20 kDa on SDS-PAGE gels 
(Figure 3.6A), which was consistent with prior reports [19]. To investigate whether the 
azide moiety in the protein was reactive under copper-free click chemistry condition, 
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both His-rTM456-N3 and rTM456-N3 were incubated with cyclooctyne functionalized 
Fluorescent dye Alexa Fluor® 647 DIBO (10 equiv, Envitrogen) in a phosphate buffer 
(pH 7.0) overnight at room temperature.  rTM456 without azide was used as a negative 
control and subjected to the same reaction conditions.  Protein samples were dialyzed 
against the buffer to remove unreacted fluorescent dye and then analyzed by SDS-PAGE.  
The gel was stained with Coomassie blue (Figure 3.6A) and the fluorescent image from 
the gel were detected using an imaging system (Typhoon 9410 Variable Mode Imager, 
Amersham Biosciences, USA) (Figure 3.6B). As a result, the band for His-rTM456-N3 and 
rTM456-N3 were fluorescent, whereas no fluorescent image was detected from rTM456 
without an azide group. These results indicated that the azide moiety in the protein was 
reactive toward the cyclooctyne and could be conjugated to cyclooctyne-containing 
molecules under copper free click chemistry condition. 
 
Figure 3.6 SDS-PAGE (12%) characterization of recombinant TM derivatives:  A. 
Coomassie blue staining, B. Fluorecence scanning 
 
3.3.4 Cofactor Activity Assay of rTM 
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In this study, protein C activation activities of the rTM were evaluated. The 
activity of rTM456 was defined as moles of produced activated protein C per min by given 
amounts of rTM456 and rTM456 conjugates in the presence of thrombin. As shown in table 
III, recombinant His-TM456-N3 and TM456-N3 have shown similar protein c activity as 
commercial full TM. Taken together, rTM456 has been successfully expressed in present 
study without apparent loss of protein C activity. 
Table III. Protein C Activation Activity of rTM  
 Full TM* His-rTM-N3 rTM-N3 
Km(μM) 0.60±0.15 0.80±0.2 
(0.90±0.2) 
0.90±0.2 
(1.0±0.5) 
kcat(min
-1
) 0.20±0.03 0.28±0.05 
(0.22±0.05) 
0.24±0.04 
(0.16±0.05) 
kcat/Km 
(min
-1
.μM
-1
) 
0.37±0.14 0.40±0.15 
(0.26±0.1) 
0.29±0.11 
(0.16±0.05) 
*commercial full TM of human, the data in parentheses from [19] 
 
3.4 Conclusion  
In this study, unnatural amino acid-azidohomoalanine was successfully 
incorporated into TM at the C terminal by directly acceptance of methionine analogs 
under help of Methionine-tRNA synthetases. This incorporation of azidohomoalanine 
provides an azide moiety for site specific conjugation through Staudinger ligation and 
Click chemistry, and makes an alternative to explore protein interaction and the effect of 
cell membrane to integral protein by membrane mimics.   
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CHAPTER IV 
SYNTHESIS AND CHARACTERIZATION OF ANTITHROMBOTIC  
LIPOSOMAL THROMBOMODULIN VIA STAUDINGER 
LIGATION 
4.1 Introduction 
Membrane proteins are becoming most investigated drug targets and have been 
studied extensively in biology sciences and pharmaceutical industry since they involve 
most of physiological process such as signal transduction, control of metabolic process 
and inspiration of immune systems. The tools today for studying and characterizing 
proteins have paved the way for membrane protein investigation and provide an 
opportunity to understand this kind of proteins and create novel drug targets. However, 
there are still some unexpected challenges to meet when membrane proteins are 
considered as novel drug targets, for example, extremely difficulty to purify, easily 
activation by removing from cell membrane and so on [1]. Liposome incorporated 
proteins provide protection from inactivation of membrane protein by mimicking real cell 
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membrane and become a very usefully tool to study physiological functions of membrane 
proteins [2, 3].  
To date, liposome incorporated proteins are usually prepared by post-insertion 
method. In this strategy, target proteins are extracted from cell membrane and form 
micelles in buffer. Then micelles containing membrane proteins are incubated with 
performed liposome to form liposome incorporated membrane proteins by fusion 
interaction between hydrophobic tail of proteins and liposome. Detergents or organic 
solvents are required for their solubilization and purification [4]. However, detergents are 
difficult to remove completely, and can lead to toxicity in vivo. Furthermore, 
conformational change of proteins could happen and decrease activity or even loss of 
function due to random orientation [5]. Chemical modification methods, namely post-
functionalization methods, provide an alternative to prepare liposome incorporated 
proteins, in which in most cases involve the coupling of biomolecules to the surface of 
preformed vesicles that carry functionalized lipid anchors [6]. Compared to post-insertion 
method, this strategy was designed to orient modification and reduced possibility of 
random confirmation. On the other hand, it provides an opportunity to incorporate 
proteins into liposome without help of hydrophobic tailor of membrane proteins, in turn, 
which makes it easier to prepare target proteins. So far, variable coupling methods have 
been studied for post-surface functionalization by using amide [7] or thiol-maleimide 
coupling [8], imine [9], hydrazone linkage [10] as well as bioorthogonal conjugation 
methods including native chemical ligation  (NCL) [11], Staudinger ligation [12] or Click 
chemistry [13]. Among of current coupling methods, the Staudinger ligation is a widely 
used method for bioconjugation in lots of applications such as DNA labeling [14], 
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peptide-peptide conjugation [15], cell surface engineering [16] as well as drug delivery 
systems [12].  This reaction occurs in native condition with high yield and without any 
catalyst and is compatible with the unprotected functional groups of wide range of 
biomolecules. 
Incorporation of non-natural amino acid into proteins provides a powerful tool to 
engineer proteins with additional functionalities for special applications, especially for 
those functionalities that cannot be introduced translationally into large proteins, as well 
as applications in protein tagging and protein conjugation. For instance, several kinds of 
methionine analogs containing azides into recombinant proteins for chemoselective 
modification have been incorporated into murine dihydrofolate reductase (mDHFR) [17]. 
This incorporation of UAAs containing azides provides very useful tool for a lots of 
application such as bioconjugation, vivo imaging, protein labeling or drug design and 
delivery by Staudinger ligation and Click chemistry. For example, site-specific 
PEGylation of human thrombomodulin has been performed to increase half-time in the 
blood via Staudinger ligation. [18]. An engineered LplA acceptor peptide (LAP) with an 
alkyl azide have been developed and further labeled in living mammalian cells which 
providing an opportunity to biochemical and imaging studies of cell surface proteins [19]. 
Particularly, TM is a type I membrane protein. The lipid bilayer in which it 
resides serves as an essential ‘cofactor’, locally concentrating and coordinating the 
appropriate alignment of reacting cofactors and substrates for protein C activation. 
Liposomes have been extensively studied as cell membrane model as well as carrier for 
delivering certain vaccines, enzymes, drugs, or genes to their active sites.  Herein, we 
have explored regio- and chemoselective functionalization of recombinant 
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thrombomodulin (TM) to liposome surface via Staudinger ligation in order to mimic the 
native endothelial antithrombotic mechanism of both TM and lipid components and thus 
will provide a more forceful than current antithrombotic agent (Figure 4. 1).  
 
Figure 4.1 Schematic Illustration of Proposed Membrane Mimetic Re-expression of 
Membrane Protein TM onto Liposome 
 
4.2 Experimental 
4.2.1 Materials and Methods 
All solvents and reagents were from commercial sources and were used as 
received, unless otherwise noted. Deionized water was used as a solvent in all 
experiments. The mouse monoclonal antibody specific to human TM was from 
COVANCE Corp. (Richmond, CA). Purified recombinant human PC and human 
thrombin were from Haematologic Technologies Inc. (Essex Junction, VT).  Human anti-
thrombin, recombinant human TM and chromogenic substrate Spectrozyme PCa were 
from American Diagnostica Inc. (Stamford, CT). L-azidohomoalanine was from AnaSpec 
Inc. (Fremont, CA). 1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC), 1,2-disteroyl-sn-
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glycero-3-phosphoethanol-amine-N-[amino(polyethylene glycol)3400](ammonium salt) 
(DSPE-PEG3400-NH2) were from Laysan Bio Inc. (Arab, AL). Cholesterol, 
dicyclohexylcarbodiimide (DCC), diphenylphosphino-4-methoxycarbonylbenzoic acid, 
hexaethylene glycol, toluene sµlfonyl chloride, imidazole, sodium azide, N-
hydroxsuccinimidobiotin, N,N-dimethylformamide and other chemicals  were from 
Sigma-Aldrich (USA).  
Mass spectrometry experiments were performed using QSTAR Elite mass 
spectrometer (Applied Biosystems, Foster City, CA). Data was conducted with Analyst® 
QS 2.0 software. Thin-layer chromatography (TLC) was performed on Whatman silica 
gel aluminum backed plates of 250 μm thicknesses on which spots were visualized with 
UV light or by charring the plate after dipping in 10% H2SO4 in methanol. Fluorescence 
imaging of glass slide was performed using a Typhoon 9410 Variable Mode Imager 
(Amersham Biosciences, USA). Dialysis was performed using cellulose membranes with 
a molecular weight cutoff of 3.5 kDa with water as solvent. 
1
H NMR spectra were 
recorded at room temperature with a Varian INOVA 300 MHz spectrometer. In all cases, 
the sample concentration was 10 mg/mL, and the appropriate deuterated solvent was used 
as an internal standard. Dynamic Light Scattering was recorded with 90Plus particle size 
analyzer (BIC). IR spectra were measured on Bruker FT-IR spectrometer (Bruker Optics 
Inc, MA) using an attenuated reflectance attachment accessory. Fluorescent spectrum was 
measured with FluoroMax-2 (ISA) 
 
4.2.2 rTM Expression and Purification from E. coli 
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rTM expression and purification were performed as the protocol in chapter IV. 
Similar procedure was used for preparation of positive control protein His-rTM and rTM 
without incorporation of azide group. Briefly, the expression plasmid TM456GGM was 
transformed into E. coli BL21 (DE3) cells. For rTM with azide will be cultured and 
expressed in M9 medium plus azidohomoalanine. While control rTM without azide 
incorporation were grown in LB media and expressed in same conditions. rTM 
purification and fusion tag removal were performed at the same conditions 
 
4.2.3 Synthesis of Anchor Lipid DSPE-PEG3400-Triphenylphosphine (DSPE-
PEG3400-TP) 
DSPE-PEG3400-NH2 (100mg, 35.8 µmol) was dissolved in 20 mL of CH2Cl2, and 
0.2 mL of triethylamine was added. After stirring for 30 min at room temperature, a 
solution of succinimidyl 3-diphenylphosphino-4-methoxycarbonylbenzoate (22 mg, 47.6 
µmol) in 50 mL of CH2Cl2 was added. The reaction mixture was stirred at room 
temperature for 24 hrs and then concentrated under vacuum to give a residue, which was 
purified by silica gel chromatography with chloroform/methanol (4: 1, v/v) to afford 
product 1 (41 mg, 9.0 µmol, 25 %). 
1
H NMR (CDCl3, 300 MHz) 8.06 (m, 1H), 7.79 (m, 
1H), 7.44 (m, 1H), 7.66 (m, 2H), 7.52-7.42 (m, 2H), 7.28-7.34 (m, 8H), 6.64 (m, 1H), 
5.19 (s, 1H), 4.34-4.20 (m, 3H), 3.95-3.80 (m, 3H), 3.80-3.50 (br. S, 44H, O-CH2-CH2-
O), 3.40-3.20 (m, 3H), 2.28 (br.s, 4H),  1.52 (br.s, 4H), 1.36-1.20 (s, 32H),  0.89 (t, J, 6.9 , 
6H), 
31
P NMR (CDCl3, 121 MHz) : -2.7. 
4.2.4 Preparation of Triphenylphosphine Functionalized Liposome 
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Triphenylphosphine functionalized liposome was prepared. DSPC and cholesterol 
at 2:1 mol ratio were used as the major components of all liposome. 1 mol % of anchor 
lipid DSPE-PEG3400-triphosphine was doped. In detail, the lipids mixture of cholesterol, 
mPEG3400, DSPE-PEG3400-TP (2: 1: 5%: 1% molar ratio) were first dissolved in 
chloroform. The solvent was gently removed on an evaporator under reduced pressure to 
form a thin lipid film on the flask wall and kept in a vacuum chamber overnight. Then, 
the lipid film was swelled in the dark with 2.5 mL PBS buffer (pH 7.4), followed 10 
freeze-thaw cycles of quenching in liquid N2 and then immersed in a 50 °C water-bath to 
form multilamellar vesicle suspension. Finally, the crude lipid suspension was extruded 
through polycarbonate membranes (pore size 600, 200, and 100 nm, gradually) at a 60 °C 
to afford small unilamelar vesicles. 
 
4.2.5 Synthesis of rTM-Liposome Conjugates via Staudinger Ligation 
rTM456-N3 (200 µg) was purified on a His-trap FF column and transferred into 50 
mL of Tris-HCl buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4).  The solution was 
added into 2 mL of triphenylphosphine-functionalized liposome (DSPE-PEG3400-TP, 1%) 
described above. The conjugation was then conducted at room temperature for up to 12 
hrs with very gentle shaking under N2 atmosphere. The unreacted rTM456-N3 was 
removed by gel filtration (1.5×20 cm column of Sephadex G-50) to generate rTM456-
liposome conjugate via Staudinger ligation DLS was used to monitor the integrity of the 
vesicles during and after the coupling reaction. 
4.2.6 Protein Assay by Bradford Method. 
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1 mL purified rTM liposome conjugate from CL-6B column was collected in a 
acetone compatible tube, followed by adding 4 mL cool acetone (-20 °C). The mixture 
was votexed and incubates for 60 mins at -20 °C, followed by centrifuging 10 mins at 
13,000-15,000 × g. Then, supernatant was removed carefully and not dislodge the protein 
pellet. Next, the acetone was allowed to evaporate from the uncapped tube at room 
temperature for 30 mins. 1 mL Tris-HCl buffer (20 mM, pH 7.4) was added for the 
downstream process and vortexed thoroughly to dissolve protein pellet. Finally, the 
protein assay was performed as instruction manual of Bradford protein assay (Bio-Rad). 
 
4.2.7 Stability Evaluation of Liposome during Staudinger Ligation and Liposomal 
rTM Conjugate 
The stability of the liposomes during coupling reaction and the final liposomal-
rTM456 conjugate products were monitored by measuring fluorescent leakage in 
comparison to the same type of liposomes unmodified having encapsulated self-
quenching concentrations of 5,6-carboxyfluorescein (85 mM) using FluoroMax-2 (ISA, 
NJ). Briefly, the lipid film composed of DSPC, cholesterol, mPEG2000, DSPE-PEG3400-TP 
(2: 1: 5%: 1% molar ratio) was swelled in the dark with 2.5 mL Tris-HCl buffer (Tris-
HCl 20 mM, NaCl 150 mM, pH 7.4) containing 85 mM 5,6-Carboxyfluorescein (5,6-CF) 
to form the multilamellar vesicle suspension. The crude lipid suspension was extruded 
through polycarbonate membranes (Millipore sizes from 600 nm, 200 nm and 100 nm, 
successively) to produce small unilamellar vesicles with an average mean diameter of 
120 ± 10 nm, as judged by DLS. Separation of the CF vesicles from non-entrapped CF 
was achieved by gel filtration chromatography, which involved passage through a 1.5×20 
  93 
cm column of Sephadex G-50. Twenty µL of reaction solution was taken and mixed with 
1980 µL of Tris-HCl buffer (pH 7.4), and then the fluorescent intensity was measured by 
using FluoroMax-2.  A control experiment was conducted, in which recombinant TM 
with azide group was replaced with recombinant TM without azide group in equal 
amounts. To evaluate extent of fluorescence release upon disruption in the conjugation, 
20 µL of 0.5 % Triton-100 solution was added into sample above to release all entrapped 
CF molecules from the liposomes and fluorescence intensity was measured. 
5, 6-carboxyfluorescein (CF) released from liposomes in PBS (pH 7.4) buffer at 
room temperature was measured over time. The excitation and emission wavelengths of 
5, 6-CF were 497 and 520 nm, respectively. The variation of the fluorescent intensity 
with release time was calculated according to the equation below  
Fraction of CF remaining in liposomes) = 1 - F/F0 
where F is the fluorescent intensity measured at any time during the experiment and F0 is 
the total fluorescent intensity measured after disrupting liposomes completely with 0.5% 
Triton X-100 in PBS (pH 7.4) buffer. 
 
4.2.8 Catalytic Cofactor Activity Assay of Liposomal rTM by Protein C Activity 
Assay  
Catalytic cofactor activity assay of rTM derivatives including His-rTM456-N3, 
rTM456-N3, and liposome-rTM456 Conjugates were analyzed by protein C assay.  The 
activity of recombinant TM456 was defined as moles of produced APC per min by given 
amounts of rTM456 protein and rTM456 conjugates in the presence of thrombin. All 
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activations of protein C by rTM conjugates were performed for 60 mins in 20 mM Tris-
HCl buffer, pH 7.4, 100 mM NaCl, 0.1% BSA, and 5 mM Ca
2+
 at 37°C. Typically, 20 
nM thrombin and different rTM concentrations (1, 1.5, and 2 nM) were incubated in the 
assay buffer. After 60 mins, 20 µL antithrombin III (3 µg/µL) and 20 µL heparin (1000 
IU/mL) were added into the solution to stop the reaction. The inhibition of protein C 
activation was completed within 5 mins at room temperature. The produced APC was 
measured through hydrolysis of a chromogenic substrate (Spectrozyme PCa) by 
comparing a standard curve, in which the concentration of APC to the rate of p-
nitroanilide (pNA) formation was measured. The hydrolysis of Spectrozyme PCa was 
performed for 10 mins in the assay buffer at 37 °C, in which pNA was produced and the 
concentration measured by monitoring at λ = 405 nm with a spectrophotometer. 
 
4.3 Results and Discussion 
4.3.1 Preparation of Triphenylphosphine Functionalized Liposome 
The synthesis of triphenylphosphine functionalized liposomes starts with the 
synthesis of anchor lipid-DSPE-PEG3400-Triphenylphosphine. First, 3-
diphenylphosphino-4-methoxycarbonylbenzoic acid NHS active ester was synthesized 
according the procedure [12]; then the NHS active ester was reacted with commercially 
available DSPE-PEG3400-NH2 to form triphenylphosphine functionalized anchor lipid by 
amidation of primary amine in the lipid and NHS active ester (Figure 4.2). With the 
anchor lipid in hand, small unilamellar vesicles composed of DSPC and cholesterol (2:1 
mol ratio), 5% mPEG2000, 1.0 mol % of the anchor lipid in Tris-HCl buffer (20 mM, pH 
7.4) were prepared by rapid extrusion through polycarbonate membrane with pore size of 
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600, 200, and 100 nm diameter, sequentially at 65 °C. In the present study, mPEG2000 
was used to improve stability of liposome in coupling reaction. This produced small 
unilamellar vesicles show an average mean diameter of 12015 nm as determined by 
dynamic light scattering.  
 
Figure 4.2 Scheme for Synthesis of DSPE-PEG3400-Triphenylphosphine 
 
4.3.2 Synthesis of rTM456-Liposome Conjugates via Staudinger Ligation 
In order to make a membrane mimetic TM conjugate, we then investigated the 
selective Staudinger ligation for conjugation of the rTM456-N3 onto triphenylphosphine 
functionalized liposomes. Briefly, liposome incorporation of anchor lipid for Staudinger 
ligation was prepared. Then, rTM456 was incubated with liposome for 12 hrs and 
followed by purification through CL-6B column chromatography to provide liposomal 
rTM456 conjugate. As  In the present study, the chemically selective post-modification 
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approach was investigated to generate the proposed rTM-liposome conjugate by taking 
the advantage of the efficient utilization of rTM on the outer leaflet and avoiding 
solubility problems in the formation of a lipid-protein conjugate. Furthermore, compared 
to traditional direct liposome formulation for reagent delivery, the strategy used here 
provides an opportunity to reduce inevitable loss of targets ligands when they are facing 
the enclosed aqueous compartment and thus become unavailable for intended interaction.  
Control experiment between rTM456 and liposome without anchor lipid was conducted 
with the same procedure. As shown in figure 4.3, the reaction between rTM456 and 
liposome with anchor lipid formed was observed as a new band after conjugation (Figure 
4.3A), while control experiment between rTM456 and liposome without anchor lipid did 
not exhibit any new bands (Figure 4.3B). These results indicated successful liposome 
modification with rTM-N3 via Staudinger ligation. 
 
Figure 4.3 Western Blot for Monitoring Conjugation by Staudinger Ligation. A: rTM-N3 
with liposome including anchor lipid; B: rTM-N3 with liposome without anchor lipid 
The conjugation efficiency of the click conjugation was evaluated by a given 
amount of rTM456-N3 and fixed anchor lipid (DSPE-PEG3400-TP) concentration in the 
liposome (1% of the lipids in liposome), in which DSPE-PEG3400-TP was in excess to 
rTM456-N3. The grafted amount of rTM456-N3 onto the liposome was calculated after gel 
filtration purification (CL 6B, GE Healthcare) by detecting unreacted rTM456-N3 in the 
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buffer and rTM456-PEG3400-DSPE formed, respectively. Acetone was used to precipitate 
proteins allowing for the physical separation of protein pellet from the liposomal solution. 
The pellet was then redissolved in Tris-HCl buffer (pH 8.0) and detected by the Bradford 
protein assay (Bio-Rad).  As a result, the conjugation yield was 21% by detecting the 
rTM-liposome conjugate formed and 30% by detecting the unreacted rTM-N3 left, 
respectively. The gap between the calculated values of direct and indirect methods might 
come from loss of unreacted rTM456-N3 during the process of purification for the indirect.  
 
4.3.3 Stability Evaluation of Liposome during Staudinger Ligation and Liposomal 
rTM Conjugate 
Dynamic light scattering (DLS) was used to monitor the reaction and verify the 
integrity of the liposome during and after the Staudinger ligation reaction.  As shown in 
Figure 4.4, there was no significant change in the size of the vesicles during and after 
conjugation reaction. The average of liposome size increased from 112 ± 10 nm (Figure 
4.4A) to 119 ± 15 nm (Figure 4.4B). After separation of the rTM-liposome conjugate 
from the reaction solution, the rTM-liposome conjugate did not show size change (Figure 
4.4C). Furthermore, there was no size change of control experiment in the presence of 
rTM456 without azide group (Data not shown here). This result indicated that the 
liposomes were intact during the reaction and purification processes. 
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Figure 4.4 DLS Evaluation of Liposome Stability during Staudinger Ligation 
Conjugation between Liposome with rTM456-N3: A. before conjugation; B. after 
conjugation; C. purified conjugate 
Fluorescent dye leakage of the same type of liposomes was conducted to further 
test whether the conjugation could provoke leakage in the liposomes during the reaction 
and the stability of liposomal conjugate. In present study, self-quenching concentrations 
of 5,6-carboxyfluorescein (5,6-CF, 85 mM) was encapsulated into inner of liposome in 
the preparation of liposome, then followed by passing through G-50 to remove free 
fluorescent dye. The leakage of fluorescent day was monitored using FluoroMax-2 (ISA) 
spectrometer. Based on the fluorescence quenching determinations in coupling reaction 
(Figure 4.5A) and rTM-liposome conjugate releasing assay (Figure 4.5B), we 
demonstrated that no apparent leakage was triggered by the conjugation reaction 
compared to the liposomes incubated in the presence of rTM456 without azide group 
(Data not shown here). This fluorescence intensity unchanging indicated that no liposome 
disruption occurred during the conjugation even extension 24 hrs. In addition, the 
conjugation of the rTM to the liposome surface may have enhanced the liposome stability 
as it exhibited significantly slower dye release between 14 days to 25 days as compared 
to the control liposome treated with rTM without azide (Figure 4.5B). These results 
indicated the compatibility of the Staudinger ligation for rTM-liposome formation, and 
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the rTM-liposome conjugate was quite stable and could be used for further activity 
evaluation. 
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Figure 4.5 Evaluation of Stability of Liposome during Staudinger Ligation Reaction (A) 
and Stability of rTM-Liposome Conjugate (B) by Monitoring Fluorescent Dye 5,6-CF 
Releasing from Liposomes. Disruption of liposomes (total in A and disruption in B) was 
conducted by adding Tris-HCl buffer containing 0.5% Triton X-100 surfactant into the 
liposome solutions. 
 
4.3.4 Catalytic Activity Assay of rTM Conjugates 
In this study, protein C activation activities of the rTM conjugates were evaluated. 
The activity of rTM456 was defined as moles of produced activated protein C per min by 
given amounts of rTM456 and rTM456 conjugates in the presence of thrombin.  All protein 
C activation assays by rTM456 and rTM456 conjugates were performed for 60 mins in a 
buffer with 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% BSA, and 5 mM Ca
2+
 at 37 °C, 
as previously reported [20]. The catalytic activity of rTM456 and rTM456 conjugates were 
evaluated via the activation of varying human protein C concentration by rTM456 and 
rTM456 conjugates in the presence of thrombin and calcium. The rate of protein C 
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activation was linear with time until at least ~20% of the protein C was activated. 
Reaction conditions (TM concentration or incubation time) were adjusted so that less 
than 10 % of the protein C was activated to ensure that the amount of activated protein C 
by TM was in the linear range. TM-phospholipid interactions have been widely 
investigated before by different research group. The fact has been proven that 
phospholipids play a positive effect on the enhancement of activation of protein C by the 
thrombin-thrombomodulin complex in the surface of islet [21] or lipid vesicles [20, 22] 
by physical incorporation. The activation of protein C by the thrombin-thrombomodulin 
complex has comparable second-order rate constants by determination of the kinetic 
parameters of activation of protein [23]. Therefore, it is the kcat/KM value that allows 
direct comparison of the effectiveness of different forms of TM in different tissues or 
organisms toward protein C. Typically, catalytic activity of TM will change by 1) altering 
the kcat, 2) altering Km for protein C. As shown in the Table 4.1, recombinant His-TM456-
N3 and TM456-N3 do not have apparent loss of activity while after conjugation, the value 
of kcat/KM of rTM-liposome conjugate has a twice to which of His-TM456-N3 or rTM456-
N3 although there was no apparent change of kcat, this change of kcat/KM mainly resulted 
from decreasing of KM which is responsible for affinity of rTM for protein C. This result 
was consistent with a previous report in which the enhancement of kcat/KM was from 
increase of affinity of rTM for protein C [20].
 
This increasing of affinity may be the result 
of using liposome as a platform which has a beneficiary effect on the configuration of the 
conjugated rTM for enhancing thrombin and protein C binding. 
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Table IV. Protein C Activation Activity of rTM and its Conjugate via Staudinger ligation 
 Full TM* His-rTM-N3 rTM-N3 rTM-liposome 
KM (μM) 0.60±0.15 0.80±0.2 
(0.90±0.2) 
0.90±0.2 
(1.0±0.5) 
0.31±0.15 
kcat (min
-1
) 0.20±0.03 0.28±0.05 
(0.22±0.05) 
0.24±0.04 
(0.16±0.05) 
0.24±0.07 
kcat/KM 
(min
-1
.μM
-1
) 
0.37±0.14 0.40±0.15 
(0.26±0.1) 
0.29±0.11 
(0.16±0.05) 
0.77±0.26 
*commercial full TM of human, the data in parentheses are from Chaikof et at [18]. 
 
4.4 Conclusion 
We demonstrated here the first example of biomimetic thrombomodulin 
conjugates which were synthesized site-specifically at the C-terminal with a chemical tag 
via Staudinger ligation. This liposomal rTM conjugate exhibited similar catalytic activity 
of natural TM with a potential to develop a more forceful antithrombotic agent.  
Furthermore, the proposed membrane-mimetic re-expression of recombinant TM onto 
liposome will provide a rational design strategy for facilitating studies of membrane 
protein functions and generating a protein-based drug 
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CHAPTER V 
SYNTHETIC BIO-INSPIRED THROMBOMODULIN CONJUGATES 
VIA COPPER-FREE CLICK CHEMISTRY FOR EXPLORING 
MEMBRANE PROTEIN’S SPECIFIC ACTIVITY 
5.1 Introduction 
TM is a glycoprotein that contains chondroitin sulfate glycosaminoglycans 
(CSGAG) attached to the D3 domain, which contributes to TM’s thrombin binding, 
stability, and plasminogen activation activities [1]. Synthetic glycopolymers with 
multiple copies of sugar moieties have shown very promising results when used as 
natural oligosaccharide mimics [2]. Glycoengineering aimed at adding carbohydrates to 
proteins to alter pharmacokinetic properties, such as increasing in vivo activity and 
prolonging the duration of action, has become a developing field in regards to the 
enhancement of protein therapeutics [3, 4]. Recently, covalent attachments of synthetic 
glycopolymers having multiple copies of sugar moieties have been explored for 
therapeutic applications [5, 6]. Therefore, we hypothesized that modification of  
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recombinant TM containing the EGF-like domains 456 (rTMEGF456) with glycopolymers 
may mimic the natural glycosylation on the TM (Figure 5.1a) and that such modifications 
may improve recombinant TM’s activity in vivo, such as reducing immunogenicity and 
extending plasma half-lives.  
Since TM is a membrane protein, it would be logical to develop a membrane 
mimetic conjugate of TM to mimic the native endothelial antithrombotic mechanism 
associated with cell membrane lipid components, thereby creating a more efficacious 
agent than current soluble TM without the membrane domain [7]. In addition, liposomes 
have been extensively studied as cell membrane models and as carriers for delivering 
vaccines, enzymes, drugs, and genes to sites of action [8]. In this study, we envisioned 
that rTM-liposome conjugates containing rTMEGF456 may provide a rational design 
strategy for facilitating studies of membrane TM’s functions while generating an optimal 
platform for exploring membrane protein-based drugs (Figure 5.1b). 
In the past, the production of such protein-conjugates, to serve as effective 
biotherapeutics, was hindered by nonspecific conjugation reactions, resulting in a variety 
of isoforms, which potentially eliminate the protein’s proper activity for the intended use. 
However, more advanced protein engineering and new bioconjugation techniques now 
permit to include unique attachment sites within peptides for numerous applications in 
protein engineering and functional studies. For example, the introduction of chemically 
unique groups into proteins by means of non-natural amino acids allows for site-specific 
functionalizations [9]. Previously, an azido-containing rTM construct was reported for 
the site-specific conjugation with a methoxy-terminated polyethylene glycol (mPEG) 
derivative via Staudinger ligation [10]. Site-specific immobilization of a rTM derivative 
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at the C-terminus through click chemistry with a suitably engineered alkyne PEG glass 
slide was also demonstrated [7].  The Cu(I)-catalyzed click chemistry has become of 
great use in modifying proteins and other macromolecules [6, 11]. However, a 
disadvantage of this reaction is the potential presence of residual copper, which can be 
potentially toxic, in the product intended for biological application [12]. Recently, to 
avoid the use of the potentially toxic copper catalyst, copper-free click chemistry has 
emerged as a popular bioorthogonal ligation strategy [13]. This reaction has been 
employed to solve many problems in chemical biology, pharmaceutical science and 
materials science. It has been used as a versatile chemistry for biomolecule modification 
[14], cell surface modification [15] and biomaterial fabrication [16] applications. In this 
study, we have explored regio- and chemoselective glyco- and liposomal 
functionalization of a recombinant TM456 derivative at the C-terminus through copper-
free click chemistry in order to afford biomimetic TM conjugates, which are expected to 
be potential anticoagulants with enhanced pharmacokinetic properties (Figure 5.1).   
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Figure 5.1 Schematic Illustration of Syntheses of Biomimetic TM Conjugates: A. rTM-
glycopolymer conjugate; B. rTM-liposome conjugate via copper-free click chemistry 
modifications. rTM456: recombinant TM containing EGF-like domains 4, 5, and 6. 
 
5. 2 Experimental 
5.2.1 Materials and Methods 
All solvents and reagents were from commercial sources and were used as 
received, unless otherwise noted. Deionized water was used as a solvent in all 
experiments. The mouse monoclonal antibody specific to human TM was from 
COVANCE Corp. (Richmond, CA). Purified recombinant human PC and human 
thrombin were from Haematologic Technologies Inc. (Essex Junction, VT).  Human anti-
thrombin, recombinant human TM and chromogenic substrate Spectrozyme PCa were 
from American Diagnostica Inc. (Stamford, CT). L-azidohomoalanine was from AnaSpec 
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Inc. (Fremont, CA). 1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC), 1,2-disteroyl-sn-
glycero-3-phosphoethanol-amine-N-[amino(polyethylene glycol)2000](ammonium salt) 
(DSPE-PEG2000-NH2) were from Avanti Polar Lipids (Alabaster, AL). DBCO-PEG4-NH2 
was from Click Chemistry Tools (Scottsdale, AZ). Glyco-Staining kits were from Geno 
Technology (St Louis, MO). Cholesterol, dicyclohexylcarbodiimide (DCC), 
diphenylphosphino-4-methoxycarbonylbenzoic acid, hexaethylene glycol, toluene 
sµlfonyl chloride, imidazole, sodium azide, N-hydroxsuccinimidobiotin, N,N-
dimethylformamide and other chemicals  were from Sigma-Aldrich (USA).  
Mass spectrometry experiments were performed using QSTAR Elite mass 
spectrometer (Applied Biosystems, Foster City, CA). Data was conducted with Analyst® 
QS 2.0 software. Thin-layer chromatography (TLC) was performed on Whatman silica 
gel aluminum backed plates of 250 μm thicknesses on which spots were visualized with 
UV light or by charring the plate after dipping in 10% H2SO4 in methanol. Fluorescence 
imaging of SDS-PAGE gels was performed using a Typhoon 9410 Variable Mode 
Imager (Amersham Biosciences, USA). Dialysis was performed using cellulose 
membranes with a molecular weight cutoff of 3.5 kDa with water as solvent. 
1
H NMR 
and 
13
C-NMR spectra were recorded at room temperature with a Varian INOVA 300 
MHz spectrometer. In all cases, the sample concentration was 10 mg/mL, and the 
appropriate deuterated solvent was used as an internal standard. Dynamic Light 
Scattering was recorded with 90Plus particle size analyzer (BIC). IR spectra were 
measured on Bruker FT-IR spectrometer (Bruker Optics Inc, MA) using an attenuated 
reflectance attachment accessory. Fluorescent spectrum was measured with FluoroMax-2.  
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5.2.2 rTM Expression in and Purification from E. coli. 
rTM expression and purification were performed as the protocol in chapter IV. 
Similar procedure was used for preparation of positive control protein His-rTM and rTM 
without incorporation of azide group.  
 
5.2.3 Synthesis of p-Amido[tetra(ethylene glycol)]-N-Dibenzylcyclooctynephenyl-β-
D-Galactopyranoside (DBCO-PEG4-CONH-Ph-Gal) 
To a vial containing 3.2 mg of p-aminophenyl-β-D-galactopyranoside and a stir 
bar, 0.1 mL Et3N was added and the reaction mixture was then allowed to stir for 15 min 
at room temperature.   After 15 min, then a 1 mL solution of dry DMF containing 9 mg 
(1.1 eqv) DBCO-PEG4-NHS ester was added via syringe.  The vial was then flushed with 
N2 (g) and capped to stir at room temperature for 24 h.  The reaction prior to work up was 
checked by TLC 1:4 MeOH/CHCl3 against the starting materials to confirm reaction 
completion.  Then the solvent in the vial was reduced to near dryness under vacuum. The 
residue was then chromatographed on silica gel using 1:4 MeOH/Chloroform solution as 
eluent.  The isolated compound, exhibiting long-wave UV-Vis fluorescence (Rf ~ 0.45, 
1:4 MeOH/Chloroform), was collected and reduced to dryness achieving DBCO-PEG4-
CONH-phenylgalactose (4.7 mg, 47%).  
1H NMR (CDCl3, 300 MHz) δ:  7.64 (d, 1H, H-
Ar of DBCO), 7.46 – 7.34 (m, 12H, H-Ar of DBCO and Ph), 7.24 (d, 1H, H-Ar of 
DBCO), 7.06 (d, 2H, H-Ph), 5.11 (d, 1H, H1-Gal), 4.84 (d, 2H, CH2 of DBCO), 3.92 (s, 
1H, H-Gal), 3.80-3.47 (m, 5H, H-Gal), 3.55 (s, 16H, CH2-PEG), 3.23 (m, 1H), 3.09 (m, 
1H), 2.92 (m, 1H), 2.60 (t, 4H, CH2COx2), 2.42 (m, 1H), 2.27 (m, 2H),  2.02 (m, 1H).  
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FTIR (cm-1):  3341, 3066 (C≡C), 2875, 2486 (C≡C), 1715, 1646, 1508, 1456, 1397, 
1226, 1076, 832. 
 
5.2.4 Synthesis of DBCO-Functionalized Glycopolymer based on Cyanoxyl-
Mediated Free Radical Polymerization 
First, lactose-based O-cyanate chain-end functionalized glycopolymer was 
synthesized from a lactose acrylamide derivative via cyanoxyl mediated free radical 
polymerization. The procedure is described in detail in previously reported work [17]. 
Briefly, Sodium nitrite (7 mg, 1.0 mmol) and 4-chloroaniline (11 mg, 0.09 mmol) was 
dissolved in 3ml mixture of H2O/THF (1:1, V/V), followed by adding HBF4 (122 mg, 1.5 
mmol) to incubate for 30 mins. Next, acrylated lactose monomer (90 mg, 13 μmol) 
NaOCN (27 mg, 0.42 mmol) and acryamide (105 mg, 13 μmol) was added sequently and 
incubated over 16 h at 60 ℃, followed by dialysis (3500 Da, MW cutoff)  to afford 
lactose based O-Cyanate Chain-end gylcopolymer (275 mg, 65 %). 
Then, DBCO Functionalized glycopolymer was synthesized directly from the 
Lactose-based O-cyanate chain-end functionalized glycopolymer by dissolving 50 mg in 
0.1 M sodium bicarbonate buffer (pH 8.3), and then by adding DBCO-PEG4-Amine (5 
mg, 9.5 μmol) dissolved in 200 μL DMSO slowly. The mixture was allowed to stir for 12 
h at room temperature, followed by dialysis (3500 Da, MW Cutoff) to remove any 
unreacted DBCO-PEG4-Amine providing the DBCO functionalized glycopolymer (35 
mg, 70%). 
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5.2.5 Synthesis of 1,2-Distearoyl-sn-glycero-3-phosphoethanol amine-N-
[(Polyethylene glycol)2000]-N-[Tetra(ethylene glycol)]-N-Dibenzylcyclooctyne (DSPE-
PEG2000-DBCO) 
To a dry 25 mL round bottom flask containing a stir a bar, DSPE-PEG2000-NH2 
(94.4 mg, 0.034 mmol) was added and the flask was then equipped with a 3-way 
stopcock and placed under vacuum for 20 min.  The sealed flask, equipped with a balloon, 
was backfilled with Ar(g) and then 3 mL of dry chloroform was added via syringe to 
dissolve the contents under stirring.  After the solid was dissolved, while stirring, DBCO-
PEG4-NHS ester dissolved in 1 mL of dry chloroform (20 mg, 0.029 mmols) was added 
via syringe slowly, dropwise over 5 min, and the mixture was allowed to stir under Ar(g) 
at room temperature for 15 min.  Then, via syringe, triethylamine (0.05 mL, 0.36 mmols) 
was added and the reaction was monitored via TLC (1:10 MeOH: CHCl3) over a 48 h 
period.  After 48 h, or upon reaction completion, the reaction mixture was then 
concentrated under reduced pressure and purified via silica gel column chromatography 
using methanol/chloroform (1:10) as eluting solvent affording pure DSPE-PEG2000-
DBCO (0.077g, 79% yield).   
1
H NMR (CDCl3, 300 MHz) δ: 8.06 (s, 3H), 7.68 – 6.6 (d, 
8H), 5.21 (s, 1H), 5.13 (d, 2H), 4.35 (d, 2H), 4.21 (t, 2H), 3.99 (m, 6H), 3.73 – 3.55 (m, 
204H), 3.10 (t, 1H), 2.70 (t, 2H), 2.47 (t, 2H), 2.29 (t, 4H), 1.59 (t, 4H), 1.35 (t, 4H), 1.26 
(t, 52H), 0.88 (t, 6H).   
13C NMR (CDCl3, 75 MHz) δ: 173.4, 173.0, 136.1, 132.1, 129.1, 
128.6, 127.8, 125.6, 108.0, 93.2 (alkyne), 70.6 (PEG), 67.2, 55.5, 45.7, 39.1, 36.8, 34.1, 
32.0, 29.71, 24.9, 22.7.  FTIR (cm-1):  3490, 2915, 2870, 2850, 2091, 1714, 1651, 1542, 
1466, 1349, 1249, 1092, 948, 843, 720.  
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5.2.6 Site-Specific Galactose-Modification of His-rTM456-N3 via Copper-Free Click 
Chemistry  
To 100 µL of 20 mM Tris-HCl buffer (pH 7.4) with 10 µg of recombinant His-
TM456-N3, DBCO-PEG4-CONH-Phenyl-galactose (1 mg) in 20 µL DMSO was added, 
and the mixture was stirred for 12 hrs at room temperature. SDS-PAGE gel (12%) was 
used to separate the reaction mixture, followed by glyco-staining and Coomassie blue 
staining to confirm reaction completion. Staining procedures were followed according to 
the manufacturers’ instructions.  
 
5.2.7 Site-Specific Glycopolymer-Modification of His-rTM456-N3 via Copper-Free 
Click Chemistry  
To 100 µL of 20 mM Tris-HCl buffer (pH 7.4) with 10 µg recombinant His-
TM456-N3, DBCO-PEG4-Glycopolymer (2 mg) in 20 µL DMSO was added, and the 
mixture was stirred for 12 h at room temperature. SDS-PAGE gel (12%) was used to 
separate the reaction mixture, followed by glyco-staining and Coomassie blue staining to 
confirm this reaction. Staining procedures were followed according to the manufacturers’ 
instructions.  
 
5.2.8 Conjugation of His-rTM-N3 to Anchor Lipid (DSPE-PEG2000-DBCO) via 
Copper-Free Click Chemistry 
To a solution of 50 µg recombinant TM456 in 400 µL 20mM Tris-HCl buffer (pH 
7.4), 0.5 mg DSPE-PEG2000-DBCO in 20 µL DMSO was added, and then the mixture 
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was stirred for 12hrs at room temperature. The efficiency of click conjugation between 
anchor lipid and recombinant TM456 has been evaluated given amount of rTM456 and 
anchor lipid over time. This conjugation was monitored by 12% SDS-PAGE gel and 
visualization of protein bands by Coomassie blue staining. At the same time, western blot 
was used to confirm the conjugate. Control experiment was conducted by incubation of 
same amount of anchor lipid into rTM456 without azide group solution of Tris-HCl buffer. 
 
5.2.9 Preparation of DBCO-Functionalized Liposomes  
DSPC (15 mg, 20.43 µmol), cholesterol (4 mg, 10.2 µmol), mPEG2000-DSPE (4.6 
mg, 1.67 µmol), DBCO-PEG2000-DSPE (2.2 mg, 0.65 mol) (2:1:5%:2% molar ratio) were 
dissolved in 3.0 mL chloroform. The lipid mixture was dried onto the wall of a 100 mL 
round-bottom flask by removing the solvent gently using a rotate evaporator under 
reduced pressure followed by placing the vessel under vacuum overnight to form a thin 
lipid film on the flask wall.  Then the lipid film was swelled in the dark with 2.5 mL Tris-
HCl buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4) to form a multilamellar vesicle 
suspension. Ten freeze-thaw cycles using liquid N2 followed by immersion in a 65 
o
C 
water bath were performed. The crude lipid suspension was extruded through 
polycarbonate membranes (Millipore size from 600 nm, 200 nm and 100 nm, 
successively) to produce small unilamellar vesicles with an average mean diameter of 
120 ± 10 nm, as determined by DLS. 
 
5.2.10 Synthesis of rTM-Liposome Conjugates via Copper-free Click Chemistry 
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His-rTM456-N3 (200 µg) was purified on a His-trap FF column and transferred 
into 50 mL of Tris-HCl buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4).  The solution 
was added into 2 mL of DBCO-functionalized liposome (DBCO-PEG2000-DSPE, 2%) 
described above. The click conjugation was then conducted at room temperature for up to 
9 h with very gentle shaking. The unreacted His-rTM456-N3 was removed by gel filtration 
(1.5×20 cm column of Sephadex G-50) to generate His-rTM456-liposome conjugate via 
copper-free click chemistry. As in the same procedures above, the targeted rTM456-
liposome conjugate was synthesized by releasing the His tag of His-rTM456-N3 and 
followed by treatment with DBCO-functionalized liposome (DBCO-PEG2000-DSPE, 1%) 
prepared above in Tris-HCl buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4). DLS was 
used to monitor the integrity of the vesicles during and after the coupling reaction. 
 
5.2.11 Protein Assay by Bradford Method 
1ml purified rTM liposome conjugate from CL-6B column was collected in a 
acetone compatible tube, followed by adding 4ml cool acetone (-20 °C). The mixture was 
votexed and incubates for 60 mins at -20 °C, followed by centrifuging 10 minutes at 
13,000-15,000 × g. Then, supernatant was removed carefully and not dislodge the protein 
pellet. Next, the acetone was allowed to evaporate from the uncapped tube at room 
temperature for 30 mins. 1ml Tris-HCl buffer (20mM, pH 7.4) was added for the 
downstream process and vortexed thoroughly to dissolve protein pellet. Finally, the 
protein assay was performed as instruction manual of Bradford protein assay (Bio-Rad). 
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5.2.12 Stability Evaluation of Liposome during Click Conjugation and Liposomal 
rTM Conjugate 
The stability of the liposomes during coupling reaction and the final liposomal-
rTM456 conjugate products were monitored by measuring fluorescent leakage in 
comparison to the same type of liposomes unmodified having encapsulated self-
quenching concentrations of 5,6-carboxyfluorescein (85 mM) using FluoroMax-2 (ISA, 
NJ). Briefly, the lipid film composed of DSPC, cholesterol, mPEG2000-DSPE, DBCO-
PEG2000-DSPE (2:1:5%:2% molar ratio) was swelled in the dark with 2.5 mL Tris-HCl 
buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4) containing 85 mM 5,6-
Carboxyfluorescein (5,6-CF) to form the multilamellar vesicle suspension. The crude 
lipid suspension was extruded through polycarbonate membranes (Millipore sizes from 
600 nm, 200 nm and 100 nm, successively) to produce small unilamellar vesicles with an 
average mean diameter of 120 ± 10 nm, as judged by DLS. Separation of the CF vesicles 
from non-entrapped CF was achieved by gel filtration chromatography, which involved 
passage through a 1.5×20 cm column of Sephadex G-50. Copper free click conjugation 
was conducted using the same procedure. Twenty µL of reaction solution was taken and 
mixed with 1980 µL of Tris-HCl buffer (pH 7.4), and then the fluorescent intensity was 
measured by using FluoroMax-2.  A control experiment was conducted, in which 
recombinant TM with azide group was replaced with recombinant TM without azide 
group in equal amounts. To evaluate extent of fluorescence release upon disruption in the 
conjugation, 20 µL of 0.5 % Triton-100 solution was added into sample above to release 
all entrapped CF molecules from the liposomes and fluorescence intensity was measured. 
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5, 6-carboxyfluorescein (CF) released from liposomes in PBS (pH 7.4) buffer at 
room temperature was measured over time. The excitation and emission wavelengths of 
5, 6-CF were 497 and 520 nm, respectively. The variation of the fluorescent intensity 
with release time was calculated according to the equation below  
Fraction of CF remaining in liposomes) = 1 - F/F0 
where F is the fluorescent intensity measured at any time during the experiment and F0 is 
the total fluorescent intensity measured after disrupting liposomes completely with 0.5% 
Triton X-100 in PBS (pH 7.4) buffer. 
 
5.2.13 Catalytic Cofactor Activity Assay of rTM Derivatives by Protein C Activity 
Assay  
Catalytic cofactor activity assay of rTM derivatives including His-rTM456-N3, 
rTM456-N3, rTM456-Galactose, rTM456-glycopolymer and liposome-rTM456 Conjugates 
were analyzed by protein C assay.  The activity of recombinant TM456 was defined as 
moles of produced APC per min by given amounts of rTM456 protein and rTM456 
conjugates in the presence of thrombin. All activations of protein C by rTM conjugates 
were performed for 60 mins in 20 mM Tris-HCl buffer, pH 7.4, 100 mM NaCl, 0.1% 
BSA, and 5 mM Ca
2+ 
at 37°C. Typically, 20 nM thrombin and different rTM 
concentrations (1, 1.5, and 2 nM) were incubated in the assay buffer. After 60 mins, 
20µL antithrombin III (3 µg/µL) and 20 µL heparin (1000 IU/mL) were added into the 
solution to stop the reaction. The inhibition of protein C activation was completed within 
5 min at room temperature. The produced APC was measured through hydrolysis of a 
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chromogenic substrate (Spectrozyme PCa) by comparing a standard curve, in which the 
concentration of APC to the rate of p-nitroanilide (pNA) formation was measured. The 
hydrolysis of Spectrozyme PCa was performed for 10 min in the assay buffer at 37°C, in 
which pNA was produced and the concentration measured by monitoring at λ = 405 nm 
with a spectrophotometer. 
 
5.3 Result and Discussion 
5.3.1 Synthesis of DBCO-PEG4-CONH-Ph-Gal and Site-specific Galactose-
Modification of His-rTM456-N3 via Copper-Free Click Chemistry 
The DBCO functionalized galactose was synthesized by reaction between NHS 
activated DBCO and primary amine in the galactoses (Figure 5.2). The product was 
characterized by 
1
H-NMR (Figure 5.3) and FTIR spectroscopy data (Figure 5.4). Finally, 
Mass spectrometry was used to detect the molecule weight. The produce was 
reconstituted in Solvent (50% acetonitrile, 50% water, and 0.1% formic acid) with 
1.0µg/ml and load into ESI mass spectrometer by providing a peak at 850.23 (Figure 5.5), 
which fits the calculated molecule weight (849.92)  
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Figure 5.2 Scheme for Synthesis of DBCO-PEG4-CONH-Ph-Gal 
 
Figure 5.3 
1
H NMR Spectrum (CD3OD/ D2O) of DBCO-PEG4-Phenyl-Galactose 
 
Figure 5.4 FTIR Spectrum (cm-1) of DBCO-PEG4-Phenyl-Galactose 
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Figure 5.5 Mass spectrum of DBCO-PEG4-Phenyl-Galactose 
Modification of proteins with carbohydrates has become a developing field in the 
enhancement of protein therapeutics [2, 18]. To test whether rTM456-azide could be 
conjugated to a dibenzylcyclooctyne (DBCO) sugar derivative, our initial glyco-
modification of the protein via copper-free click chemistry was carried out with a DBCO-
containing galactose (DBCO-PEG4-CONH-Ph-β-Gal), followed by glyco-staining and 
Coomassie blue staining to confirm the reaction product, respectively. rTM456 without an 
azide group was used as a control for this experiment. The employment of the glyco-stain 
for carbohydrate detection allowed for the detection of attached carbohydrate based on a 
carbohydrate-specific periodic acid Schiff (PAS) staining method, in which the cis-diol 
sugar groups were oxidized to aldehydes and then subsequently reacted with Schiff 
reagent to yield a magenta band [19]. As shown in Figure 5.6, only the sample containing 
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His-rTM456 with azide and DBCO-PEG4-CONH-Ph-β-Gal (Lane 1) exhibited a magenta 
band whereas sample of His-rTM456 without azide and DBCO-PEG4-CONH-Ph-β-Gal 
(Lane 2, positive control) and sample of His-rTM456 with azide and Phenyl-galactose 
without DBCO (Lane 3, negative control) showed no glyco-staining.  Additionally, 
Coomassie blue staining for all proteins in the gel did not exhibited any new bands, since 
the molecular mass of the DBCO-PEG4-CONH-Ph-β-Gal is only 849 Da, too small to 
alter protein migration pattern to be detected on SDS-PAGE.  These results indicated the 
successful modification of His-rTM456-azide with the galactose derivative via copper-free 
click chemistry. 
 
Figure 5.6 SDS-PAGE (12%) Characterization of Site Specific Glyco-Modification of 
rTM via Copper Free Click Chemistry (pH 8.0, room temperature (RT), 6 hrs): A. Glyco-
staining,  B. Coomassie blue staining: Lane 1: His-rTM-N3 treated with DBCO-PEG4-
CONH-Ph-β-Gal; Lane 2 : His-rTM treated with DBCO-PEG4-CONH-Ph-β-Gal; and 
Lane 3: His-rTM-N3 treated with pNH2-Ph-Gal. 
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5.3.2 Synthesis of DBCO-functionalized Glycopolymer and Site-Specific 
Glycopolymer-Modification of His-rTM456-N3 via Copper-Free Click Chemistry  
Synthesis of DBCO-functionalized glycopolymer was conducted in two steps 
(Figure 5.7). Fist, lactose-based O-cyanate chain-end functionalized glycopolymer was 
synthesized from a lactose acrylamide derivative via cyanoxyl mediated free radical 
polymerization in our lab [17]. Then the glycopolymer was incubated with DBCO-PEG4-
Amine in bicarbonate buffer (pH 8.3) for 12h at room temperature to provide the DBCO 
functionalized glycopolymer with 70% yield. This product was characterized by 1H 
NRM spectroscopy data (Figure 5.8).  
 
Figure 5.7 Synthesis of DBCO-Functionalized Glycopolymer 
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Figure 5.8 
1
H NMR Spectrum (CD3OD/D2O) of DBCO-Functionalized Glycopolymer  
Next, a site-specific glycopolymer modification of the recombinant TM was 
investigated using a DBCO-PEG4-Glycopolymer via copper-free click chemistry as 
indicated above. SDS-PAGE was used to separate and identify the conjugate, followed by 
glyco-staining and Coomassie blue staining, respectively. As shown in Figure 5.9, only 
the sample including His-rTM456-N3 (with azide) (Lane 1) showed a magenta band of 
high molecular weight (>130 kDa) while the His-rTM456 (without azide) treated with 
DBCO-PEG4-Glycopolymer (Lane 2, positive control) and His-rTM456-N3 (with azide) 
treated with glycopolymer without DBCO  (Lane 3, negative control) exhibited no glyco-
staining (Figure 5.9A). Coomassie blue staining (Figure 5.9B) showed the same high 
molecular weight band that appeared on the glyco-staining gel on Lane 1 containing His-
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rTM456-N3 (with azide) and DBCO-PEG4-Glycopolymer, and the protein band at ~51 
kDa corresponding to unreacted His-rTM456 azide.   
 
Figure 5.9 SDS-PAGE (12%) Characterization of Site-Specific Glycopolymer-
Modification of rTM via Copper Free Click Chemistry (pH 8.0, RT, 6 hrs): A. Glyco-
staining, B. Coomassie blue staining:  Lane 1: His-rTM-N3 treated with DBCO-PEG4-
Glycopolymer; Lane 2: His-rTM treated with DBCO-PEG4-Glycopolymer; and Lane 3: 
His-rTM-N3 treated with glycopolymer (without DBCO). 
The molecular weight achieved for the glycopolymer-protein conjugate was 
higher than anticipated on the SDS-PAGE gel.  This in part could be due to the fact that 
the glycopolymer attached is a long chain molecule consisting of lactose and amide side 
chains with very little charge, which may hamper the conjugate’s ability to move within 
the electronic field during electrophoresis. This phenomena has been observed in 
previous report when using glycopolymer to modify streptavidin [20]. Neither the 
positive nor did the negative controls exhibit the formation of any new bands after 
Coomassie blue staining. These results indicated successful glycopolymer modification 
of the rTM456-N3 via copper-free click chemistry. Specifically, the reaction between two 
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chain-ends of protein and glycopolymer facilitates the formation of uniform conjugate 
with a point of attachment that is regio- and chemoselective. 
 
5.3.3 Synthesis of Anchor Lipid (DSPE-PEG2000-DBCO) and Conjugation of His-
rTM-N3 to Anchor Lipid via Copper-Free Click Chemistry 
The anchor lipid with DBCO was synthesized by reaction between commercially 
available NHS activated DBCO and lipid by forming stable amide bond with removing 
NHS group (Figure 5.10). TLC plate was used to monitor the process. After 48h, there 
was no more anchor lipid produced to confirm completion of this reaction. Finally, the 
mixture was load into silica gel column chromatography to provide purified anchor lipid 
by methanol/chloroform (1:10) as eluting solvent with 79% yield. The anchor lipid with 
DBCO was characterized by 
1
H-NMR (Figure 5.11), 
13
C-NMR (5.12) and FTIR 
spectroscopy data (Figure 5.13). 
 
 
Figure 5.10 Scheme for Synthesis of DSPE-PEG2000-DBCO 
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Figure 5.11 
1
H NMR Spectrum (CD3OD/D2O) of DSPE-PEG2000-DBCO 
 
Figure 5.12 
13
C-NMR Spectrum (CD3OD/D2O) of DSPE-PEG2000-DBCO 
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Figure 5.13 FTIR Spectrum of DSPE-PEG2000-DBCO 
 
With the anchor lipid (DSPE-PEG2000-DBCO) in hand, copper free click 
conjugation of His-rTM456-N3 to anchor lipid was investigated to explore conjugation 
condition. To a solution of recombinant His-TM456-N3, anchor lipid was added, and then 
the mixture was stirred for 9hrs at room temperature. The efficiency of click conjugation 
between anchor lipid and recombinant His-TM456-N3 was evaluated given amount of His-
rTM456-N3 and anchor lipid over time. This conjugation was monitored by 12% SDS-
PAGE gel and visualization of protein bands by Coomassie blue staining. At the same 
time, western blot was used to confirm the conjugate. Control positive control (His-
rTM456-N3 and lipid without DBCO group) and negative control (His-rTM456 and anchor 
lipid with DBCO group) were conducted in the same procedure was conducted by 
incubation of same amount of anchor lipid into rTM456 without azide group solution of 
Tris-HCl buffer.  As result, a new broad band was observed in the conjugation while 
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there was no any new band in the positive control and negative control experiment by 
conducting His-rTM456 without azide group in its C terminal. According the SDS-PAGE 
and Western Blot above, the conjugation was ended in 6 hours and there was no more 
conjugate produced with continuously increasing incubation time to 9 hrs. Based on the 
SDS-PAGE and Western blot (Figure 5.14), about 90% of rTM456 was modified by 
anchor lipid by copper click conjugation. 
 
Figure 5.14 SDS-PAGE and Western Blot for Monitoring Conjugation of His-rTM-Azide 
with DSPE-PEG2000-DBCO (lipid anchor only) 
5.3.4 Synthesis of Liposomal rTM456 Conjugates via Copper-Free Click Chemistry 
In order to make a membrane mimetic TM conjugate, we then investigated the 
selective click chemistry conjugation of the rTM456-N3 onto alkyne-PEG functionalized 
liposomes.  Conventional methods in the preparation of surface functionalized liposomes 
involve the initial synthesis of the key lipid-ligand conjugate, followed by formulation of 
the liposome with other lipid components. In this liposome formulation method, some of 
the valuable ligands inevitably face the enclosed aqueous compartment and thus become 
unavailable for their intended interaction with their target molecules. Therefore, in a 
liposome formulation for reagent delivery, it is unrealistic if the targeting ligand is only 
available in minimal amounts, which may hinder the ability of the carrier to reach its 
destination and to properly interact with its target especially when multivalent binding is 
necessary.  Furthermore, lipid-ligand conjugates may have poor solubility and stability in 
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aqueous solvent, or are incompatible with various manufacturing processes. In this study, 
a chemically selective post-modification approach was investigated to generate the 
proposed rTM-liposome conjugate. Briefly, liposomes bearing the anchor lipid DBCO-
PEG2000-DSPE were prepared, followed by incubation with His-rTM456-N3 in a Tris-HCl 
buffer (Tris-HCl 20 mM, NaCl 150 mM, pH 7.4).  The click conjugation was then 
conducted at room temperature for up to 9 h under very gentle shaking. The unreacted 
His-rTM456-N3 was then removed by gel filtration (1.5 x 20 cm column of Sephadex G-50) 
to afford the targeted His-rTM456-liposome conjugate. SDS-PAGE and Western blotting 
were used to monitor the conjugation progress.  As shown in Figure 5.15 (A and B), the 
His-rTM456-PEG2000-DSPE formed was observed as a new band after conjugation, while 
neither the positive nor the negative control experiments exhibited any new bands. The 
His-rTM456-PEG2000-DSPE conjugate was further confirmed by BaCl2/I2 staining which 
visualizes the PEG molecules of the conjugate (Figure 5.15C), whereas both positive 
(His-rTM456-N3 and liposome without anchor lipid, Figure 5.15D) and negative (His-
rTM456 and liposome with anchor lipid, Figure 5.15E) control conjugations did not show 
His-rTM456-PEG2000-DSPE conjugate formation. These results indicated successful 
liposomal modification of the rTM-N3 via copper-free click chemistry. As in the same 
procedures above, the targeted rTM456-liposome conjugate was synthesized by releasing 
the His tag of His-rTM456-N3 and followed by treatment with liposomes bearing the 
anchor lipid DBCO-PEG2000-DSPE in Tris-HCl buffer (Tris-HCl 20 mM, NaCl 150 mM, 
pH 7.4).  As shown in Figure 6.15F, Western blotting confirmed the new band formed 
upon the rTM456-N3 reacted with the liposome. 
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The conjugation efficiency of the click conjugation was evaluated by a given 
amount of rTM456-N3 and fixed anchor lipid (DCBO-PEG2000-DSPE) concentration in the 
liposome (2% of the lipids in liposome). The grafted amount of rTM456-N3 onto the 
liposome was calculated after gel filtration purification (CL6B, GE Healthcare) by 
detecting unreacted rTM456-N3 in the buffer and rTM456-PEG2000-DSPE formed, 
respectively, in which DCBO-PEG2000-DSPE was in excess to rTM456-N3. Acetone was 
used to precipitate proteins allowing for the physical separation of protein pellet from the 
liposomal solution. The pellet was then redissolved in Tris-HCl buffer (pH 8.0) and 
detected by the Bradford protein assay (Bio-Rad).  As a result, the conjugation yield was 
~60% by detecting the rTM-liposome conjugate formed and ~68% by detecting the 
unreacted rTM456-N3 left, respectively. 
  
Figure 5.15 SDS-PAGE (12%) Characterization of Site Specific Liposomal Modification 
of His- rTM-N3 via Copper Free Click Chemistry (pH 8.0, RT): A. Coomassie blue 
staining; B. Western blot; C. barium chloride/iodine staining; D. positive control: His-
rTM456-N3 treat with liposome without anchor lipid; E. negative control: His-rTM456 and 
liposome with anchor lipid DBCO-PEG2000-DSPE, F. Western blot for rTM456-N3 treated 
with liposome with anchor lipid DBCO-PEG2000-DSPE 
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5.3.5 Stability Evaluation of Liposome during Click Conjugation and Liposomal 
rTM Conjugate  
Dynamic light scattering (DLS) was used to monitor the reaction and verify the 
integrity of the liposome during and after the click conjugation reaction.  As shown in 
Figure 5.16, there was no significant change in the size of the vesicles during and after 
conjugation reaction. The average of liposome size increased from 118 ± 5 nm (Figure 
5.16A) to 140 ± 5 nm (Figure 5.16B). After separation of the rTM-liposome conjugate 
from the reaction solution, the rTM-liposome conjugate did not show size change (Figure 
5.16C). Furthermore, there was no size change of control experiment (119 ± 10 nm) in 
the presence of rTM456 without azide group (Figure 5.16D). This result indicated that the 
liposomes were intact during the reaction and purification processes. 
 
Figure 5.16 DLS monitoring of liposome stability during copper free click chemistry 
conjugation between liposome (DBCO-PEG2000-DSPE, 2%) and rTM456-N3 (without His-
tag): A. before conjugation; B. after conjugation; C. purified rTM-liposome conjugate; D. 
control: liposome (DBCO-PEG2000-DSPE, 2%) treated with rTM456 (without N3) 
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To test whether the conjugation could provoke leakage in the liposomes during 
the reaction and the stability of liposomal conjugate, fluorescent dye leakage of the same 
type of liposomes having encapsulated self-quenching concentrations of 5,6-
carboxyfluorescein (5,6-CF, 85 mM) was monitored using FluoroMax-2 (ISA) 
spectrometer. Based on the fluorescence quenching determinations (Figure 5.17A) and 
rTM-liposome conjugate releasing assay (Figure 5.17B), we demonstrated that no 
apparent leakage was triggered by the conjugation reaction compared to the liposomes 
incubated in the presence of rTM456 without azide group. This fluorescence intensity 
unchanging indicated that no liposome disruption occurred during the click conjugation 
even after 12 h. In addition, the conjugation of the rTM to the liposome surface may have 
enhanced the liposome stability as it exhibited significantly slower dye release between 
14 to 21 days as compared to the control liposome treated with rTM without azide 
(Figure 5.17B). These results indicated the compatibility of the copper-free click 
chemistry for rTM-liposome formation, and the rTM-liposome conjugate was quite stable 
and could be used for further activity evaluation 
 
Figure 5.17 Evaluation of Stability of Liposome during Click Conjugation Reaction (A) 
and Stability of rTM-Liposome Conjugate (B) by Monitoring Fluorescent Dye 5,6-CF 
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Releasing from Liposomes. Disruption of liposomes was conducted by adding PBS 
buffer containing 0.5% Triton X-100 surfactant into the liposome solutions. 
 
5.3.6 Catalytic activity assay of rTM conjugates 
In this study, protein C activation activities of the rTM conjugates were evaluated. 
The activity of rTM456 was defined as moles of produced activated protein C per min by 
given amounts of rTM456 and rTM456 conjugates in the presence of thrombin.  All protein 
C activation assays by rTM456 and rTM456 conjugates were performed for 60 mins in a 
buffer with 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% BSA, and 5 mM Ca
2+
 at 37 °C, 
as previously reported [21]. The catalytic activity of rTM456 and rTM456 conjugates were 
evaluated via the activation of varying human protein C concentration by rTM456 and 
rTM456 conjugates in the presence of thrombin and calcium. The rate of protein C 
activation was linear with time until at least ~20% of the protein C was activated. 
Reaction conditions (TM concentration or incubation time) were adjusted so that less 
than 10% of the protein C was activated to ensure that the amount of activated protein C 
by TM was in the linear range. As shown in Table 5.1, there was no activity change upon 
glyco-modification of rTM456 with either galactose or lactose-containing glycopolymer. 
However, rTM-liposome conjugates had a 2-fold higher kcat/KM value than that of either 
His-TM456-N3 or rTM456-N3, even though there was no apparent change of kcat.  This 
change in kcat/KM mainly was due to a decreased Km value, which represents the affinity 
of rTM for protein C. This result was consistent with a previous report of increased 
kcat/KM values due to an higher affinity of rTM for protein C [22]. This increased affinity 
may result from using liposome as a platform, which mimics endothelial cell lipid 
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membrane and has a beneficiary effect on the conformation of the conjugated rTM for 
enhancing thrombin and protein C binding. 
Table V. Protein C Activation Activity of rTM and its Conjugates via Copper Free Click 
Chemistry 
 Full TM* His-rTM-N3 rTM-N3 rTM-Gal rTM-GP 
rTM-
liposome 
KM (μM) 0.60±0.15 0.80±0.2 
(0.90±0.2) 
0.90±0.2 
(1.0±0.5) 
0.95±0.22 0.87±0.15 0.33±0.17 
kcat (min
-1
) 0.20±0.03 0.28±0.05 
(0.22±0.05) 
0.24±0.04 
(0.16±0.05) 
0.22±0.12 0.18±0.17 0.23±0.17 
kcat/KM 
(min
-1
.μM
-1
) 
0.37±0.14 0.40±0.15 
(0.26±0.1) 
0.29±0.11 
(0.16±0.05) 
0.25±0.14 0.18±0.11 0.71±0.32 
*commercial full TM of human, Gal: galactose, GP: glycopolymer. The data in 
parentheses are from Chaikof et at. [10] 
5.4 Conclusion 
We demonstrated here the first example of biomimetic TM conjugates that were 
synthesized by site-specific conjugation of recombinant TM at the C-terminal with 
glycopolymer and liposome via copper-free click chemistry. The protein conjugation 
method presented here has distinct advantages over traditional methods. First, the site-
specific, chemo- and bio-orthogonal conjugation provides a simple and convenient route 
to uniform protein conjugation in short time and good yields. Second, mild conjugation 
conditions and low temperatures minimize the chance of protein denaturation. The rTM-
liposome conjugate showed a 2-fold higher kcat/KM value for protein C activation than 
that of the rTM456, which indicated that the biomimetic lipid membrane has a beneficiary 
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effect on the rTM’s activity. Continued studies of in vitro and in vivo antithrombotic 
activity of these TM conjugates and their pharmacokinetic properties are under 
investigation. Overall, the proposed glyco-engineering of recombinant TM with 
glycopolymer and membrane-mimetic re-expression of recombinant TM onto liposome 
provide a rational design strategy for facilitating studies of membrane glycoprotein TM 
functions and generating a TM-based antithrombotic drug. 
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CHAPTER VI 
AZIDE-REACTIVE LIPOSOME FOR CHEMOSELECTIVE AND 
BIOCOMPATIBLE LIPOSOME IMMOBILIZATION AND GLYCO- 
LIPOSOMAL MICROARRAY FABRICATION 
(Partial results are from Ma, Y., Zhang, H. L., Sun, X-L. Langmuir. 2011, 27, 13097- 
13103 and Ma, Y., Zhang, H. L., Sun, X-L. Bioconjug. Chem. 2010, 21, 1994-1999)  
6.1 Introduction 
Immobilization of liposome onto solid surface has shown a great potential in 
biological and biomedical research and applications [1]. This discipline has been inspired 
by that liposome structurally retains the properties inherent in natural lipid membranes, 
and functionally can serve as model of biomembrane and can encapsulate both 
hydrophobic and hydrophilic compounds such as drug and gene for delivery applications 
[2]. For example, immobilized liposomes have been investigated as model systems 
presenting lipid membranes for bioseparation [3], biosensor [4], and nanobioreactor [5] 
applications. Recently, immobilized liposomes onto a biomedical device have been 
considered as a potential local drug delivery system, which release drug immediately to 
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the environment surrounding the device, and reduce the toxic effects on other organisms 
and thus enhance the therapeutic effect of the drug [6]. In addition, liposome microarray 
has been explored recently for applications in membrane biophysics, biotechnology, and 
colloid and interface science [7]. 
Surface-immobilized liposomes can be fabricated through either noncovalent such 
as bio-affinity interaction or covalent bond formation by synthesizing anchor group 
modified liposomes. Conventionally, the anchor group modified liposomes are prepared 
by direct liposome formation method, in which the anchor lipid is synthesized first and 
followed by formulation of the liposome with all other lipid components. In this direct 
liposome formation method, however, some anchor-lipid conjugates may have limited 
solubility and stability in solvent, or are incompatible with various stages of preparation, 
or even may have difficulty to form liposome due to the loss of its amphiphilic property. 
It is well known that the shape of the self-assembled liposomes may be influenced by the 
nominal geometric parameters of its molecule such as polar head surface, tail volume and 
chain length [8]. Alternatively, anchor group modified liposomes can be synthesized by 
chemical modification of reactive preformed liposomes [9]. Variable successes using 
amide [10] or thiol-maleimide coupling [11] as well as by imine [12] or hydrazine 
linkage [13] have been reported. However, non-chemoselective, harsh reaction conditions 
and low efficiency of most these methods limited their practical applications. 
Azide-based ligation reactions have been expensively explored for highly 
sensitive and biocompatible bioconjugation [14-16], polymer and materials science [17, 
18] and drug discovery [19, 20]. Specifically, the azide is a versatile bioorthogonal 
chemical reporter. Its small size and stability in physiological settings have enabled 
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azide-functionalized metabolic precursors to hijack the biosynthetic pathways for 
numerous biomolecules, including glycans [21], proteins [15, 22], lipids [23] and nucleic 
acid-derived cofactors [24] and therefore can afford a variety of azide-containing 
biomolecules for biomedical applications. Three reactions have been reported for tagging 
azide-labeled biomolecules. One of these, the Staudinger ligation capitalizes on the 
selective reactivity of phosphine and azide to form an amide bond [14, 25, 26]. The other 
two involve the reaction of azide with alkyne to give triazole, a process that is typically 
very slow under ambient conditions. The Cu(I)-catalyzed azide-alkyne cycloaddition also 
known as "click chemistry", accelerates the reaction by use of a toxic copper catalyst [27, 
28]. The copper may residue inside of the liposomes and thus cause problem in clinical 
application. Recently, the strain-promoted [3 + 2] cycloaddition removes the requirement 
for cytotoxic copper by employing cyclooctynes that are activated by ring strain [29, 30]. 
However, two triazole regioisomers forms during the conjugation, which affords 
complicated products without controlling [31]. Most recently, we have demonstrated that 
Staudinger ligation of triphenylphosphine-carrying liposome with azide-containing 
biomolecules as a chemoselective liposome surface functionalization approach [32]. The 
high specificity, high yield, biocompatible and the lack of residual copper reaction 
condition natures of the Staudinger ligation approach make it an attractive alternative to 
all currently used protocols for liposome surface functionalization. Herein, we 
investigated expanded application of this azide reactive liposome for efficient and 
chemical selective liposome surface immobilization and microarray fabrication 
applications (Figure 6.1). Specifically, microarray of liposome carrying 
triphenylphosphine onto azide-modified glass slide and further glyco-modification with 
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azide-containing carbohydrate provides a cytomimetic glycoarray, which may find 
important biomedical applications such as studying carbohydrate-protein interaction and 
toxin and antibody screening and so on. 
 
Figure 6.1 Illustration of Chemically Selective and Biocompatible Liposome Surface 
Functionalization and Immobilization via Staudinger Ligation 
 
6.2 Experimental 
6.2.1 Materials and Methods  
1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC), 1,2-disteroyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)2000] (ammonium salt) (DSPE-
PEG2000), 1,2-disteroyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene 
glycol)2000] (ammonium salt) (DSPE-PEG2000-biotin), 1,2-dipalmitoyl-sn-glycerol-3-
phosphoethanolmine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (DPPE-NBD) were purchased 
from Avanti Polar Lipids (Alabaster, AL, USA). Cholesterol, dicyclohexylcarbodiimide 
(DCC), diphenylphosphino-4-methoxycarbonylbenzoic acid, hexaethylene glycol, 
toluene sulfonyl chloride, imidazole, sodium azide, N-hydroxsuccinimidobiotin, N,N-
dimethylformamide  were purchased from Sigma (USA). All other solvents and reagents 
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were purchased from commercial sources and were used as received, unless otherwise 
noted. Deionized water was used as a solvent in all experiments. 
Instrumental analysis. Dynamic Light Scattering was measured with 90plus 
particle size analyzer (Brookhaven Ins. Co., USA). Atomic force microscopes were 
carried out using PicoPlus 3000 (Molecular Imaging, USA) and Fluorescence imaging 
were obtained by Typhoon 9410 Variable Mode Imager (Amersham Biosciences, USA). 
 
6.2.2. Synthesis of Anchor Lipid DSPE-PEG2000-Triphenylphosphine (1) 
DSPE-PEG2000-NH2 (100 mg, 35.8 µmol) was dissolved in 20 mL of CH2Cl2, and 
0.2 mL of triethylamine was added. After stirring for 30 min at room temperature, a 
solution of succinimidyl 3-diphenylphosphino-4-methoxycarbonylbenzoate (33 mg, 71.6 
µmol) in 50 mL of CH2Cl2 was added. The reaction mixture was stirred at room 
temperature for 24 h and then concentrated under vacuum to give a residue, which was 
purified by silica gel chromatography with chloroform/methanol (4:1, v/v) to afford 
product 1 (32 mg, 28.5 %). 
1
H NMR (CDCl3, 300 MHz) 8.06 (m, 1H), 7.79 (m, 1H), 7.44 
(m, 1H), 7.66 (m, 2H), 7.52-7.42 (m, 2H), 7.28-7.34 (m, 8H), 6.64 (m, 1H), 5.19 (s, 1H), 
4.34-4.20 (m, 3H), 3.95-3.80 (m, 3H), 3.80-3.50 (br. S, 44H, O-CH2-CH2-O), 3.40-3.20 
(m, 3H), 2.28 (br.s, 4H),  1.52 (br.s, 4H), 1.36-1.20 (s, 32H),  0.89 (t, J, 6.9 , 6H), 
31
P 
NMR (CDCl3, 121 MHz) : -2.7.  
 
6.2.3. Synthesis of Azidoethyl-Tetra (ethylene glycol) Ethylamino Biotin (2) 
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Triethylamine (0.03 mL, 0.02 mmol) was added to a solution of amino-11-azido-
3, 6, 9-trioxanundecane [20] (54 mg, 0.176 mmol) in DMF (3.5 mL). After the solution 
was stirred for 30 min, a solution of N-hydroxsuccinimidobiotin (50 mg, 146 mmol) was 
added. The reaction mixture was stirred for 12 h at room temperature and then 
concentrated under vacuum to give a residue, which was purified by silica gel column 
chromatography using acetone: hexane (4:1, v/v) as eluent to afford 2 (41 mg, 44%). 
1
H 
NMR (CD3OD, 300 MHz) : 6.75 (br. S, 1H), 6.75 (br. S, 1H), 6.52 (br. S, 1H), 5.88 (br. 
S, 1H), 4.51 (m, 1 H, -CH-1-Biotin), 4.32 (m, 1 H, -CH-4-Biotin), 3.70-3.63 (m, 16 H, -
O-(CH2CH2O)4-PEG), 3.56 (m, 2 H, -O-CH2CH2-N3), 3.39 (m 4 H, -CH2-NH and -O-
CH2CH2-N3), 3.24 (m 1 H, -CH-3-Biotin), 2.92 (dd, 1 H, J = 4.8, 12.8 Hz, -CH-2a-
Biotin), 2.71 (m 1 H, -CH-2b-Biotin), 2.23 (t, 1 H, J = 7.6 Hz, -CH2CO-Biotin), 1.76-
1.63 (m, 4 H, -(CH2)2-Biotin), 1.50-1.40 (m, 2 H, -(CH2)-Biotin). 
 
 
Figure 6.2 Scheme for Synthesis of Amino-11-Azido-3, 6, 9-Trioxaundecane 
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6.2.4 Preparation of Biotin-Liposome via Staudinger Ligation  
First, triphenylphosphine functionalized liposome was prepared. DSPC and 
cholesterol at 2:1 mol ratio were used as the major components of all liposome. For 
liposome biotinylation, 0.5 mol % of anchor lipid DSPE-PEG2000-triphosphine was 
doped. To visualize the liposome immobilized onto the solid surface, all kinds of 
liposome were incorporated with DPPE-NBD (0.5 mg, 0.6 mol %). In detail, the mixture 
of lipids was first dissolved in chloroform. The solvent was gently removed on an 
evaporator under reduced pressure to form a thin lipid film on the flask wall and kept in a 
vacuum chamber overnight. Then, the lipid film was swelled in the dark with 2.5 mL 
PBS buffer (pH 7.4), followed 10 freeze-thaw cycles of quenching in liquid N2 and then 
immersed in a 50 oC water-bath to form multilamellar vesicle suspension. Finally, the 
crude lipid suspension was extruded through polycarbonate membranes (pore size 600, 
200, and 100 nm, gradually) at a 60 
o
C to afford small unilamelar vesicles. 
 Next, triphenylphosphine functionalized liposome incubated with biotin-PEG6-
azide to provide biotinylated liposome. In detail, to 2.5 mL of triphosphine-liposome in 
PBS (pH 7.4) above, 1 mL of biotin-PEG6-azide (30 mg, 56 µmol) in PBS (pH 7.4) was 
added; then the reaction mixture was incubated at room temperature for 6 h in an argon 
atmosphere. The unreacted biotin-PEG6-azide was removed by gel filtration (1.5 × 20 cm 
Column of Sephadex G-50). The size of liposomes during the Staudinger ligation was 
monitored over time by using 90Plus particle analyzer.  
 
6.2.5 Preparation of Biotin-Liposome via Direct Liposome Formation  
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DSPC (43.2 mg, 54.7 µmol), cholesterol (10.6 mg, 27.4 µmol), DSPE-PEG2000-
Biotin (2.5 mg, 0.83 µmol) (2: 1: 1 % molar ratio) in 3 mL of chloroform. The solvent 
was gently removed on an evaporator under reduced pressure to form a thin lipid film on 
the flask wall and kept in a vacuum chamber overnight. Then, the lipid film was swelled 
in the dark with 2.5 mL PBS buffer (pH 7.4), followed 10 freeze-thaw cycles of 
quenching in liquid N2 and then immersed in a 50 
o
C water-bath to form multilamellar 
vesicle suspension. Finally, the crude lipid suspension was extruded through 
polycarbonate membranes (pore size 600, 200, and 100 nm, gradually) at a 60 
o
C to 
afford small unilamelar vesicles. 
 
6.2.6 Immobilization of Biotin-Liposome onto Streptavidin Glass Slide 
Immobilization of the biotinylated liposomes above was performed by incubating 
with streptavidin-glass slide (Xenopore Corp) in a 5 mg/mL of biotin-liposome 
suspension (total lipid concentration) at room temperature for 4 hrs, followed by 
removing the un-immobilized liposomes in the surface of glass slide. The glass slide was 
washed by rinsing with PBS buffer for 1 hrs and then replacing with new buffer solution, 
and repeated three times. 
 
6.2.7 Liposome Array Based on Staudinger Ligation 
 The liposome prepared above was diluted to desired lipid concentration (2.0 
mg/mL, total lipid concentration) by PBS (pH 7.4) buffer, then was printed onto  azide-
PEG6-functionalized glass slide followed by incubating for 2.0 hrs at room temperature. 
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Next, the liposome-immobilized glass slide was washed by rinsing with PBS (pH 7.4) 
buffer for 2.0 hrs and repeated three times to remove unbound liposomes. 
 
6.2.8 Staudinger Glyco-Functionalization of Immobilized Liposome 
The liposome prepared above was printed onto azide-PEG6-functionalized glass 
slide followed by incubating for 2.0 hrs at room temperature. Then the immobilized 
liposome carrying triphenylphosphine was incubated with 2-azideethyl-lactoside in PBS 
buffer (pH 7.4, 40 mg/mL) at room temperature for 2.0 hrs, followed by removing the 
glass slide from the reaction solution. The glass slide was then washed by rinsing with 
PBS (pH 7.4) buffer for 2.0 hrs and repeated three times. 
 
6.2.9 Specific Lectin Binding onto Lactosylated Immobilized Liposome 
The lactosylated liposome immobilized onto glass slide was incubated with lectin 
(Arachis hypogae, FITC-labeled, Sigma) in PBS (pH 7.4) buffer solution (50 g/mL) at 
room temperature for 2.0 hrs, followed by removing the glass slide from the reaction 
solution. The glass slide was the washed by rinsing with PBS (pH 7.4) buffer for 2.0 hrs 
and repeated three times 
 
6.2.10 OG488 Labeling of rTM456 
TM456 was labeled with OG488 succinimidyl ester as described with 
modifications [33]. Briefly, to a solution of 150 μL of carbonate-bicarbonate buffer (pH 
9.0), 50 μL of OG488 solution (10 mg/mL in DMSO) was added, followed by 150 μL 
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aqueous TM456 solution (2 mg/mL). The mixture was gently vortexed at room 
temperature in the dark for 2 hrs. After the coupling reaction, the unreacted OG488 was 
removed by dialysis using centrifuge devices with a cutoff molecular weight of 10,000 
Dalton. 
 
6.2.11 rTM Conjugation to Immobilized Liposome by Staudinger Ligation 
The liposome prepared above was printed onto azide-PEG6-functionalized glass 
slide followed by incubating for 2.0 hrs at room temperature. Then, the immobilized 
liposome carrying triphenylphosphine was incubated with rTM456 labeled by OG488 in 
Tris-HCl buffer (pH 7.4, 0.5mg/mL) at room temperature for 2.0 hrs, followed by 
removing the glass slide from the reaction solution. The glass slide was then washed by 
rinsing with PBS (pH 7.4) buffer for 2.0 hrs and repeated three times. Fluorescence 
imaging of glass slide was performed to explore whether rTM456 was conjugated to 
immobilized liposome by using a Typhoon 9410 Variable Mode Imager (Amersham 
Biosciences, USA). 
 
6.2.12 Measurement of Releasing Kinetics of 5, 6-Carboxyfluorescein from 
Liposome 
5, 6-carboxyfluorescein (CF) released from free liposomes, immobilized 
liposomes, and glycosylated immobilized liposomes in PBS (pH 7.4) buffer at room 
temperature was measured over time. The excitation and emission wavelengths of 5, 6-
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CF were 497 and 520 nm, respectively. The variation of the fluorescent intensity with 
release time was calculated according to the equation below  
Fraction of CF remaining in liposomes) = 1 - F/F0 
where F is the fluorescent intensity measured at any time during the experiment and F0 is 
the total fluorescent intensity measured after disrupting liposomes completely with 0.5% 
Triton X-100 in PBS (pH 7.4) buffer. 
 
6.3 Results and Discussion 
6.3.1 Chemically Selective Liposome Biotinylation and Its Immobilization 
Streptavidin/biotin-based liposome immobilization has been widely used by 
synthesizing biotin-presenting liposome [34-36]. Conventionally, the biotin anchor group 
modified liposome is synthesized by direct liposome formation method, in which the 
biotin-lipid is mixed with all other lipid components to afford a liposome with biotin 
oriented both outside and enclosed aqueous compartment. In the present study, we 
explored azide reactive pre-prepared liposome carrying PEG-triphenylphosphine for 
chemically selective liposome surface biotinylation through Staudinger ligation with 
azide-containing biotin [Figure 6.3]. First, the terminal triphenylphosphine carrying 
anchor lipid DSPE-PEG2000-triphenylphosphine 1 was synthesized by amidation of 
commercially available DSPE-PEG2000-NH2 with 3-diphenylphosphino-4-
methoxycarbonylbenzoic acid NHS active ester synthesized as described in our previous 
study [15]. Next, small unilamellar vesicles composed of phospholipids (DSPC) and 
cholesterol (2:1 mol ratio) and 1.0 mol % of the anchor lipid 1 were prepared by rapid 
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extrusion through polycarbonate membrane with pore size of 600, 200, and 100 nm 
diameter, sequentially at 65 
o
C.  This produced predominately small unilamellar vesicles 
showed an average mean diameter of 120 ± 12 nm as judged by dynamic light scattering 
(DLS) (Figure 6.3A). Finally, conjugation of azide-PEG6-biotin (2) to the preformed 
liposomes was performed in PBS buffer (pH 7.4) at room temperature in an argon 
atmosphere for 6 hrs. The azide-PEG6-biotin (2) was synthesized by amidation of amino-
11-azido-3,6, 9,trioxaundecane [16] with commercially available biotin NHS ester 
(Sigma). DLS technique was used to verify the integrity of the vesicles during and after 
the coupling reaction. As shown in Figure 6.3B, there is no significant size change of the 
vesicles observed after biotinylation reaction. Therefore, the reaction condition above 
does not alter the integrity of the liposomes and thus are harmless for liposome surface 
modification. 
 
Figure 6.3 Liposome Surface Biotinylation via Studinger Ligation 
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Figure 6.4 DLS Monitoring of Size Change of Liposome before Biotinylation (A) and 
after Biotinylation Reaction (B) 
 
Next, streptavidin binding assay was examined to determine the success of the 
biotinylation and whether the grafted biotin residues are easily accessible at the surface of 
liposomes. It is well known that one streptavidin molecule is able to bind four biotin 
molecules and the presence of streptavidin could induce aggregation of surface 
biotinylated liposome. The biotin/streptavidin combination measurement was performed 
by incubating streptavidin with the biotinylated liposome in PBS buffer (pH 7.4) at room 
temperature. After 2 hrs, streptavidin-induced aggregation of the biotinylated liposomes 
was confirmed by DLS (Figure 6.4A), while there was no aggregation observed for the 
liposomes without biotinylation (Figure 6.4B). Furthermore, the presence of free biotin 
(5.0 mM) prevented aggregates formation (not shown), confirming that the aggregation 
was due to the specific recognition of the biotin residues on the surface of the liposome 
by streptavidin. These results indicated that the liposome surface has been biotinylated 
successfully and grafted biotin on the liposome surface was easily accessible. Similar 
A B 
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result was obtained with the direct-formed biotin-liposome as positive control (Figure 
6.5C). 
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Figure 6.5 DLS Monitoring of Streptavidin Binding Assays of Biotinylated Liposomes: 
Post Biotinylated Liposomes (A), Plain Liposomes without Biotin (B) and Direct 
Biotinylated Liposomes (C) 
Immobilization of the biotinylated liposome was performed by incubating with 
streptavidin-coated glass slide (Xenopore Corp) in PBS buffer (pH 7.4) at room 
temperature for 2 hrs followed by washing with PBS buffer (pH 7.4) three times. To 
confirm the immobilized liposome on the glass slide surface, fluorescent imaging study 
was examined with post biotinylated liposome and direct biotinylated liposome, 
respectively. To visualize liposomes in the fluorescence image, DSPE-NTB was doped in 
both liposomes as component for detecting by a microplate reader. As shown in Figure 4, 
both post biotinylated liposome (Figure 6.6A) and direct biotinylated liposome (Figure 
6.6B) yielded a uniform fluorescence image, while there was no apparent fluorescence 
image observed for the nonbiotinylated liposomes (Figure 6.6C). Taken together, these 
results indicated that the immobilization of intact liposomes was achieved with biotin 
anchor.  
A B C 
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Figure 6.6 Fluorescence Image of Immobilized Liposomes onto Streptavidin-Coated 
Glass Slides: Post biotinylated liposomes (A), Direct Biotinylated Liposomes (B) and 
Plain Liposomes without Biotin (C) Doping with DSPE-NTB 
 
To examine whether the immobilization reaction condition could provoke 
liposome disruption, fluorescent dye releasing kinetics from the liposome during 
immobilization reaction was investigated. Briefly, we have exposed our standard 
conditions to the same type of liposomes but with encapsulated selfquenching 
concentration (85 mM) of 5,6-CF. On the basis of the fluorescence quenching 
determinations (Figure 6.7A), we could demonstrate that less than 7.2 % leakage of the 
total loading was triggered during the immobilization reaction (2.0 hrs) compared with 
5.2 % leakage for the same liposome during storage without reaction (2.0 hrs). The 
leakage percentiles were calculated by destroying liposomes with surfactant 0.5 % Triton 
X-100 in PBS (pH 7.4) buffer to release all 5,6-CF encapsulated after 2.0 h reaction. 
These results indicated that the immobilization reaction condition is harmless for 
liposome integrity. Continually, the subsequent fluorescent dye releasing kinetics over 
time for the non-destroyed immobilized liposomes was examined to verify the stability of 
the intact immobilized liposome in PBS (pH 7.4) buffer at room temperature. It was 
found that immobilized liposome showed a constant leakage of approximately 25 %/day 
A
 A  
B
 A  
C
 A  
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for three days (Figure 6.7B), whereas free liposome in PBS (pH 7.4) solution showed a 
leakage rate of approximately 20 %/day (Figure 6.7C), which is slightly less than that of 
immobilized liposome. The extended fluorescent dye releasing results further 
demonstrated that intact liposomes had been successfully immobilized onto the glass 
slide and showed sustained stability as well. 
 
Figure 6.7 5,6-CF Releasing from Liposome during the Immobilization Reaction: before 
Reaction, after Reaction, and after Adding 20 μL of 0.5 % Triton X-100 (A); the 5,6-CF 
Releasing Kinetics from Immobilized Liposome (B); the 5,6-CF Releasing Kinetics from 
Free Liposome (C); and the 5,6-CF Releasing Kinetics from Glycosylated Immobilized 
Liposome (D) during Storage in PBS (pH 7.4) Buffer at rt during 0-72 hrs, and after 
Adding 20 μL of 0.5 % Triton X-100 at the Final Point. 
To provide further evidence that immobilized liposomes remain intact on the glass 
slide surface, atomic force microscope (AFM) was used since it is a powerful tool for 
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investigating surface-related physical and chemical properties in nanoscale. As shown in 
Figure 6.8, typical AFM images of immobilized liposomes have been observed for post 
biotinylated liposome (Figure 6.8A) and direct biotinylated liposome (Figure 6.8B) as 
well, while there were no immobilized liposomes observed for the non-biotinylated 
liposomes (Figure 6.8C). These results further confirmed the successful immobilization 
of intact liposomes via biotin anchor. 
 
 
 
 
 
 
Figure 6.8 AFM Image Study of Immobilized Liposomes onto Streptavidin-Coated Glass 
Slides: Post Biotinylated Liposomes (A), Direct Biotinylated Liposomes (B) and Plain 
Liposomes without Biotin (C) 
 
6.3.2 Chemically Selective Liposomal Microarray Fabrication 
Liposome microarrays are versatile tools in biomedical research, as they can be 
used for applications in membrane biophysics, biotechnology, and colloid and interface 
science [7]. Most liposome microarrays were fabricated through bioaffinity between 
anchoring group on the liposome surface and the counterpart group on the solid surface, 
such as biotin/streptavidin7 and DNA hybridization [37]. In the current study, we 
A
 A  
B
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C
 A  
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explored chemically selective liposome microarray and its rTM conjugation performed 
by the Staudinger ligation of a performed liposome carrying PEG-triphosphine with 
azide-functionalized solid surface. The azid-PEG6-glass slide was used as model surface 
for liposome microarray and was prepared by amidation of commercially available amine 
glass slide (Xenopore, Co) with azido-PEG6-COO-NHS (Figure 6.9) 
 
Figure 6.9 Scheme for Synthesis of Azido-PEG6-COO-NHS 
In order to confirm the intact liposome immobilized on the glass slide surface, 
fluorescence imaging study was conducted by doping DSPE-Rodamine (1 mol%, Avanti 
Polar Lipid, Inc) in the liposome lipid bilayer so as to label lipid membrane and by 
encapsulating 5,6-carboxyfluorescein (5,6-CF, Sigma) (50 mM) into the liposome so as 
to image the inner compartment of the liposome. As results, either detecting 5,6-CF 
(Figure 6.10A) or Rodamine (Figure 6.10B) yielded fluorescence image of the 
immobilized liposome for azide-PEG glass slide treated with liposomes carrying anchor 
group triphenylphosphine, while there was no apparent fluorescence image observed for 
azide-PEG glass slide treated with liposomes without anchor group triphenylphosphine 
(Figure 6.10C). These results indicated that the immobilization of intact liposomes was 
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achieved through Staudinger ligation. Next, glyco-modification was performed by 
incubation of the immobilized liposomes carrying thriphenylphosphine left over on the 
liposome exterior surface with 2-azideethyl-lactoside [38] in PBS buffer (pH 7.4) at room 
temperature under an argon atmosphere for 2 hrs. Specific lectin binding assay was 
investigated to confirm the success of glycosylation and whether the grafted lactose 
residues are easily accessible at the surface of the immobilized liposomes. The binding 
assay was conducted by incubating lactosylated arrayed liposomes in the solution of -
galactose binding lectin (Arachis hypogae, 120 kDa, FITC-Labeled, Sigma) in PBS (pH 
7.4) buffer at room temperature for 2.0 hrs, followed by washing with PBS (pH 7.4) 
buffer three times. As shown in Figure 5, the specific binding of fluorescent labeled lectin 
was observed on the lactosylated immobilized liposome spots (Figure 6.10E), while there 
was no apparent fluorescence image observed for liposomes with anchor group 
triphenylphosphine unmodilied (Figure 6.10D) and glycosylated liposome with lactose 
pre-incubated lectin (Figure 6.10F) . These results indicated specific binding of lectin 
onto the lactosylated arrayed liposomes. 
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Figure 6.10 Fluorescence Images of Arrayed Liposomes: Selectively Exciting 5,6-CF 
Encapsulated in the Liposome (A) and for Selectively Exciting PE-Rhodamine 
Embedded in the Liposome Membrane (B), and Liposomes without Anchor Group 
Triphenylphosphine (C); Fluorescence Image of Lectin (FITC-labeled Arachis hypogaea) 
Binding onto the Arrayed Liposome: Liposomes with Anchor Group Triphenylphosphine 
(D), Glycosylated Liposome (D), and Glycosylated Liposome with Lactose Pre-incubated 
Lectin (E): Bar Size:  500 nm 
 
6.3.3 rTM456 Conjugation to Immobilized Liposome by Staudinger Ligation 
Next, liposome microarray and its rTM conjugation were designed as figure 6.11. 
In the step I, immobilization of the preformed liposomes was performed by incubating 
azide-PEG-glass slides with preformed liposomes in Tris-HCl buffer, followed by 
addition of MeO-PEG2000-triphenylphosphine to quench the azide group left on the glass 
slide. The unreacted liposomes were removed by washing with Tris-HCl buffer to afford 
immobilized liposome. In the step II, glass slide with immobilized liposome was 
incubated into OG488 labeled rTM456 for 2hrs at room temperature under argon 
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atmosphere, in which OG488 was use for identification of rTM modification by 
providing fluorescence image. Positive control (liposome with anchor lipid incubated 
with non-functionalized glass slide) and negative control (liposome without anchor lipid 
with functionalized glass slide) experiments were performed at the same conditions. As 
shown in Figure 6.12, only rTM conjugated liposome (Figure 6.12C) yielded a uniform 
fluorescence, while positive control (non-functionalized glass slide) (Figure 6.12A) or 
negative control (without anchor lipid in the liposome) (Figure 6.12B) did not show 
apparent fluorescence image. Taken together, these results indicated that rTM 
successfully conjugated to triphenylphosphine functionalized liposome to afford 
liposomal rTM conjugate as mimics of natural TM. 
 
 
Figure 6.11 Procedure for Liposome Immobilization and Its rTM Conjugation 
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Figure 6.12 Fluorescent Image of rTM Conjugation to Immobilized Liposome: Positive 
control (Non-functionalized Glass Slide) (A), Negative Control (without Anchor Lipid) 
(B) and Immobilized Liposomal rTM Conjugate (C). 
 
6.4 Conclusion 
An azide reactive liposome has been developed for efficient and chemically 
selective liposome surface modification and glyco-liposome microarray fabrication 
applications. Specifically, microarray of liposome carrying triphenylphosphine onto 
azide-modified glass slide and further glyco-modification with azide-containing 
carbohydrate were demonstrated via Staudinger ligation. The high specificity and 
efficiency and biocompatible reaction condition natures of this liposome biotinylation 
approach make it an attractive alternative to all currently used protocols for liposome 
surface functionalization. Notably, since there is no catalyst used in modification and 
immobilization reaction, therefore, there is no concern of catalyst left in the resultant 
liposome that is common problem in other liposome modification methods. The reported 
method will provide a useful platform in the application of immobilized liposome system 
for a variety of biomedical researches and practices.  
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CHAPTER VII  
SUMMARY AND FUTURE PROSPECT 
7.1 Summary of Current Work 
Cardiovascular diseases are still most like reasons for death in Unite States 
although lots of attentions and efforts have been achieved to fight against them. 
Antithrombotic agents that prevent blood clotting have been used for both the prevention 
and treatment of active vascular thrombosis. However, current antithrombotic therapies 
have met limited success due to the risk of series bleeding, hemorrhagic complication. In 
present study, our goal of the proposed research is to develop recombinant 
thrombomodulin (rTM)-based antithrombotic agents by synthesizing TM-liposome 
conjugate that mimics the native endothelial TM’s antithrombotic mechanism. We 
hypothesize that combination of antithrombotic membrane protein TM into lipid 
membrane mimetic assembly (liposome) through recombinant and bioorthogonal 
conjugation techniques provides a rational strategy for generating novel and potential 
antithrombotic agent. The major accomplishments are briefly summarized below. 
First, a chemo- and bio-orthogonal liposome surface functionalization through 
Staudinger ligation reaction has been developed. Briefly, an unprotected carbohydrate 
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derivative with an azide group was conjugated to the surface of vesicles presenting a 
synthetic lipid carrying a terminal triphosophine function. The liposomes were kept 
integrity during the reaction as measuring liposome size by dynamic light scattering 
(DLS) and monitoring fluorescent dye releasing kinetics. Moreover, the successful 
liposome surface functionalization was assessed by agglutination experiments using 
lectin, which show that the grafted galactose residues were perfectly accessible on the 
surface of liposome. This versatile approach, which is particularly suitable for the ligation 
of water-soluble molecules and without catalyst, is anticipated to be useful in the 
coupling of many other ligands onto liposome surface. 
Second, to develop recombinant thrombomodulin (rTM)-based antithrombotic 
agents that mimics the native endothelial TM’s antithrombotic mechanism, natural amino 
acid-azidohomoalanine was successfully incorporated into TM at the C terminal by 
directly acceptance of methionine analogs under help of Methionine-tRNA synthetases. 
This incorporation of azidohomoalanine provides an azide moiety for site specific 
conjugation through Staudinger ligation and Click chemistry, and makes an alternative to 
explore protein interaction and the effect of cell membrane to integral protein by 
membrane mimics. 
Third, with azido-functionalized TM in hand, chemo-and bio-orthogonal methods 
including Staudinger and Click chemistry have been explored to synthesize liposomal 
rTM conjugate, respectively. In this study, protein C activation activities of the liposomal 
rTM conjugates were evaluated. His-TM456-N3 and TM456-N3 do not have apparent loss of 
activity while after conjugation, the value of kcat/KM of rTM-liposome conjugate has a 
twice to which of His-TM456-N3 or rTM456-N3 although there was no apparent change of 
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kcat, this change of kcat/KM mainly resulted from decreasing of KM which is responsible 
for affinity of rTM for protein C. This result was consistent with a previous report in 
which the enhancement of kcat/KM was from increase of affinity of rTM for protein C. 
This increasing of affinity may be the result of using liposome as a platform which has a 
beneficiary effect on the configuration of the conjugated rTM for enhancing thrombin 
and protein C binding. Therefore, the proposed membrane-mimetic re-expression of 
membrane protein domains onto liposome will provide a rational design strategy for 
facilitating studies of membrane protein functions and generating a membrane protein-
based drug 
In addition, the azide reactive liposome has been developed for efficient and 
chemically selective liposome surface modification and glyco-liposome microarray 
fabrication applications. Specifically, microarray of liposome carrying 
triphenylphosphine onto azide-modified glass slide and further glyco-modification with 
azide-containing carbohydrate were demonstrated via Staudinger ligation. The high 
specificity and efficiency and biocompatible reaction condition natures of this liposome 
biotinylation approach make it an attractive alternative to all currently used protocols for 
liposome surface functionalization. Notably, since there is no catalyst used in 
modification and immobilization reaction, therefore, there is no concern of catalyst left in 
the resultant liposome that is common problem in other liposome modification methods. 
The reported method will provide a useful platform in the application of immobilized 
liposome system for a variety of biomedical researches and practices. 
7.2 Future Prospects  
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Although recombinant thrombomodulin (rTM)-based antithrombotic agents that 
mimic the native endothelial TM’s antithrombotic mechanism have been successfully 
developed via chemo-and bio-orthogonal methods including Staudinger and Click 
chemistry, there still remain several prospects to explore before becoming an novel and 
potential antithrombotic agent. Further investigation will seek to define the capacity of 
the rTM-liposome to limit thrombus formation both in vitro and in vivo and to determine 
their pharmacokinetics. The following researches are expected to be conducted 
continually.  
 
7.2.1 Evaluation of Anticoagulant Activity of rTM-Liposome Conjugates 
Activated partial thromboplastin time (aPTT) and thrombin-clotting time (TT) are 
common method to analysize coagulation disorder and first-order method to assay 
anticoagulant therapy. Therefore, aPTT and TT should be performed to determine the 
anticoagulant property of liposomal rTM conjugates.  
 
7.2.2 Antithrombotic Activity Assay of rTM-Liposome  
Evaluation of antithrombotic activity of TM in vivo is another important way to 
demonstrate its efficacy and therapeutically promising application. A method for 
antithrombotic activity assay by tissue factor-induced microthromboembolism in mice 
should be investigated.  
 
7.2.3 Measurement of the Circulating Half-life of rTM Liposome 
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To remain appropriate drug retention time, namely circulation lifetime in vivo,   is 
very important to keep the maximum effect with minimizing the risk of toxicity. Lots of 
novel drug candidates suffered from relatively short half-time and lose the opportunity to 
develop a clinical drug. Particularly, to prolong life time is more challenging for protein 
based drugs compared to traditional small drug molecules due to living system clearance 
as well as enzymatic digestion.  In the future, measurement of the circulating half-time of 
rTM-liposome should be performed to assay the effect of liposome and PEG on half-time 
of liposomal rTM conjugate. ELISA and functional APC assay can be performed to assay 
half-time of liposomal rTM conjugate according to previous study.  
 
 
 
 
 
 
 
 
 
 
 
